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ABSTRACT 
Probiotics, defined as live microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host, are considered a valid and novel alternative 
for the prevention and treatment of female urogenital tract infections. Lactobacilli, the 
predominant microorganisms of the healthy human vaginal microbiome, can be 
included as active pharmaceutical ingredients in probiotics products. Several 
requirements must be considered or criteria fulfilled during the development of a 
probiotic product or formula for the female urogenital tract. This review deals with the 
main selection criteria for urogenital probiotic microorganisms: host specificity, 
potential beneficial properties, functional specifications, technological characteristics 
and clinical trials used to test their effect on certain physiological and pathological 
conditions. Further studies are required to complement the current knowledge and 
support the clinical applications of probiotics in the urogenital tract. This therapy will 
allow the restoration of the ecological equilibrium of the urogenital tract microbiome as 
well as the recovery of the sexual and reproductive health of women. 
 
Keywords: Probiotics. Pharmabiotics. Female urogenital tract. Urogenital tract 
infections. Potential beneficial properties. Technological characteristics. Clinical assays. 
 
Abbreviations 
API: Active pharmaceutical ingredients 
AV: Aerobic vaginitis 
BV: Bacterial vaginosis 
CFU: Colony forming units 
CRL: Centro de Referencia para Lactobacilos Culture Collection 
CVF: Cervicovaginal fluid 
EFSA: European Food Safety Authority 
FGM: Food Grade Microorganisms 
FGT: Female genital tract 
GRAS: Generally Regarded As Safe 
HM: Human microbiome 
ISAPP: International Scientific Association for Probiotics and Prebiotics 
LAB: Lactic acid bacteria 
PAMP: Molecular patterns associated with pathogens 
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QPS: Qualified Presumption of Safety 
TLR: Toll-like receptors 
UGTI: Urogenital tract infections 
UTI: Urinary tract infections 
VVC: Vulvovaginal candidiasis 
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1. Introduction 
Human beings are colonized by a diverse and complex collection of microbes, 
contributing all of them to host nutrition, development of the immune system, response 
to pathogens and mucosal cell differentiation and proliferation. The knowledge of these 
communities and their gene contents has been referred collectively as the human 
microbiome (HM), supported by a NIH-funded project consortium [1,2]. The human 
microbiome is a complex system of many microbial communities inhabiting a diversity 
of environmental niches throughout the human body. Until recently, technological 
limitations precluded the global characterization of the human microbiome in terms of 
composition, diversity and dynamics. Massive parallel sequencing and other high 
throughput approaches have offered novel ways to explore and examine the microbiota 
from different human body cavities that includes eukaryotes, archae, bacteria and 
viruses. The sequences of more than 1000 bacterial genomes are now available and it is 
interesting to remark that bacteria numbers within an individual are estimated higher 
than number of human cells by an order of magnitude [1-3].  
The increase in microbiota-related research has provided important advances 
toward the identity of specific microorganisms and microbial groups or microbial 
molecules, their functions and relationships between healthy-unhealthy status, being 
essential to the overall health of the host by performing relevant physiological 
functions, protection against pathogens and driven the development of the immune 
system during neonatal life. Additional projects are investigating the association of 
specific components and dynamics of the microbiome with a variety of disease 
conditions. HM project encountered an estimated 81-99% of the genera, enzyme 
families and community configurations occupied by the healthy western microbiome 
[1,2]. Studies on this HM have revealed that healthy individuals differ remarkably in the 
microbes that occupy gut, skin and vagina. But the microbial genera are highly 
dependent on the colonization of microorganisms carried out after the newborn delivery, 
on the prevalent environmental conditions and on different host factors that are 
modified through the time. There is some remarkable similarities in the bacterial species 
present in people with different ethnicity [3,4]. 
The microbiome colonizing the human body provides the host a huge coding and 
metabolic activities as will be described later [1,2,5-8]. Among this microbiota there are 
health-promoting indigenous species that are commonly consumed as live supplements 
[9]. 
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Lactic acid bacteria (LAB) and some related genera were isolated from almost 
all the mucosa and human tracts. Referred specifically to the genus Lactobacillus, there 
are around 202 different described species up to present 
(http://www.bacterio.net/lactobacillus.htlm) and more than 100 with their chromosomal 
DNA sequenced. Their genomes have sizes varying from 1.8 to 3.3 MB, and their G+C 
content range from 33 to 51%. In such a way, a Lactobacillus core genome has been 
described, constituted by 383 sets of orthologous genes, designed as Lactobacillus core 
genome [5,10,11]. 
 
2. Vaginal microbiome. Ecological and functional aspects 
Vaginal microbiota forms a mutually beneficial relationship with their host and 
has a major impact on health and disease. In the vaginal microbiome, lactobacilli 
constitute the dominant proportion (80%) of bacteria inhabiting the healthy women’s 
vagina [1,2,5-7,12,13]. Some LAB strains have found to be endogenous from healthy 
human vagina, where there is a rather stable microbiota [14-16]. LAB members are 
consistently detected in healthy vaginal microbiota of different ethnic groups and/or 
women living in different geographical locations [7,17-22]. Four main species were 
identified: Lactobacillus crispatus, Lactobacillus iners, Lactobacillus jensenii and 
Lactobacillus gasseri, along with other lactobacilli at lesser extent, as Lactobacillus 
acidophilus, Lactobacillus ruminis, Lactobacillus rhamnosus and Lactobacillus 
vaginalis [7,15]. Our understanding of the vaginal microbial community composition 
and structure has significantly broadened as a result of studies using cultivation-
independent methods based on the analysis of 16S ribosomal RNA (rRNA) gene 
sequences [6,10,11,15,23,24].  
The high abundance of LAB is strongly associated with a healthy vagina, 
whereas a low abundance of LAB is more prevalent in women with a pathological 
condition [6-9,13,14,16,19,25-27]. Eventhough the four species indicated above are 
predominantly detected in human vagina, co-dominance between LAB is not very 
frequent [1,7,15]. In asymptomatic, otherwise healthy women, several kinds of vaginal 
microbiota exist, the majority often dominated by species of Lactobacillus, while others 
are composed of a diverse array of anaerobic microorganisms [7,8,13,15,21,27]. Ravel 
et al. [7] characterized the vaginal microbiome of asymptomatic, sexually active women 
who represented four ethnic groups (white, black, Hispanic, and Asian). The vaginal 
bacterial communities were classified according to community composition in five 
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major groups. Communities in group I were dominated by L. crispatus, whereas groups 
II, III and V were dominated by L. gasseri, L. iners and L. jensenii, respectively. Group 
IV was highly heterogeneous and had higher proportions of strictly anaerobic bacteria, 
including Prevotella, Dialister, Atopobium, Gardnerella, Megasphaera, Peptoniphilus, 
Sneathia, Eggerthella, Aerococcus, Finegoldia, and Mobiluncus. The proportions of 
each community group varied among the four ethnic groups. Communities with high 
Nugent scores (criterion used to diagnose bacterial vaginosis) were most often 
associated with communities in group IV, but were also observed in communities 
belonging to other groups.  
Most of the Lactobacillus species described above were related to the healthy 
vagina, but some other authors suggested that L. iners was frequently isolated from non-
healthy subjects [24]. Molecular-based and culture-based techniques used in 
combination have indicated that in the absence of lactobacilli, normality can be 
maintained by more fastidious lactic acid producing bacteria [15]. The dominant 
Lactobacillus species may differ racially or geographically, but the principle of 
numerical dominance persists [6,7,17,18,20-22,27], indicating that the LAB may be 
adapted to the vagina and possess characteristics enabling them to thrive in that 
environment [28].  
The temporal dynamics of vaginal communities are poorly known because few 
studies have been done in which the same individuals are frequently sampled and 
variation in community composition assessed over time using cultivation-independent 
methods [24,26,29,30]. Fredricks [31] suggested that the vaginal microbiota can be 
highly dynamic, with dramatic shifts in bacterial composition and concentrations in 
response to numerous endogenous and exogenous factors. Ravel et al. [7] proposed 
different hypothesis that could explain the variation of vaginal community composition 
over time: 1) “dynamic equilibrium hypothesis”, in which the composition of a 
community is comparatively invariant over time and exists in a single dynamic 
equilibrium; 2) “community space hypothesis”, in which each community can and does 
occupy any position in community space over time and throughout a woman’s lifetime; 
3) “alternative equilibrium states hypothesis”, wherein a woman’s community can 
change over time, but the number of alternative states are limited in number and 
governed by unknown factors, and 4) “community resilience hypothesis”, in which the 
composition and structure of a vaginal community can change to a transitional state in 
response to disturbance, but the resistance and resilience of a community determine the 
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extent and duration of a change. Further studies are required to understand the dynamics 
of vaginal communities. 
On the other hand, there was an inverse correlation between Lactobacillus ratio 
and dryness and an increased bacterial diversity in women experiencing moderate to 
severe vaginal dryness, as indicated by Hummelen et al. [32]. In healthy participants, L. 
iners and L. crispatus were generally the most abundant species, countering the long-
held view that lactobacilli are absent or depleted in menopause. Vaginal dryness and 
atrophy were associated with down-regulation of human genes involved in maintenance 
of epithelial structure and barrier function, while those associated with inflammation 
were up-regulated consistent with the adverse clinical presentation [32]. 
 
3. Urogenital tract infections (UGTI) and uses of urogenital probiotics 
3.1. UGTI 
The urogenital microbiome composition is influenced by genetics, hormone 
levels, hygiene, disease and use of contraceptives and antibiotics, among others factors 
[14,16,19,27,33,34]. The genetic polymorphism of each person is defined as small 
changes in the DNA sequence of a gene occurring between individuals that influence 
the production of high or low levels of anti- or pro-inflammatory factors [35,36]. The 
genetic polymorphism varies among the different ethnic groups and influences the 
urogenital microbial composition and the susceptibility to UGTI [37-40]. The imbalance 
of the female urogenital ecosystem, which can be caused by different external or 
internal factors, negatively affects the protective, indigenous microbiota and favors the 
income or the overgrowth of pathogenic or potentially pathogens causing UGTI 
[14,19,36].  
The UGTI, their costs and frequencies are detailed in depth in other reviews of 
this special issue. Briefly, sexual transmitted infections and others infections affecting 
the reproductive tract (in sexually active, pregnant or post-menopausal women) are of 
main importance and with a high frequency at all the social and economic level human 
groups [14,19,22,24,41-45]. Single urinary tract infections (UTI) episodes are very 
common, mainly in adult women, in which there is a 50-fold predominance compared 
with adult men [46-52]. Recurrent UTI are also frequent, occurring in up to one-third of 
women after the first episode [53]. The major types of UGTI are the acute and recurrent 
bacterial and fungal infections, and certain anatomical characteristics as well as 
hormonal effects make women more susceptible to them [42]. Bacterial vaginosis (BV), 
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vulvovaginal candidiasis (VVC) and infections of urethra, bladder, ureter, kidney or 
cervix affect 300 million women per year worldwide; in USA alone, UTI resulted in an 
annual health-care costs of about U$1.6 billion [45]. 
The UGTI are associated to high morbidity and mortality of mothers, fetuses and 
the newborns. As example, preterm birth was recently related to a multiplicity of 
infections [43,54,55], in such a way that while bacterial ascent from the vaginal tract 
was recognized as the primary cause of intrauterine infection, the microbiomes of the 
other tracts were shown to be involved by means of hematogenous spread [56]. Most of 
the UGTI are treated with a different set of traditional antimicrobial drugs 
[47,49,51,57]. Eventhough these therapies have improved the quality of the life of 
patients, they have produced a long list of inconvenient, as adverse effects, limitations 
of use in pregnant women, high costs and recurrence rates, increase of resistant and 
multiresistant microbial strains and the horizontal genetic resistance transference 
evidenced more frequently [57-60].  
 
3.2. Probiotics 
The description of the main LAB species isolated from the vaginal tract of 
women around the world and their differences between healthy and non-healthy patients 
(as mentioned in item 2) supports the idea of the rebalancing the urogenital microbiome 
with some specific and well characterized Lactobacillus strains. Moreover, the long list 
of disadvantages associated to the conventional antimicrobial drug uses are important 
reasons to search for novel and alternative treatment options for UGTI, such as 
probiotics. 
Probiotics are defined as “live microorganisms that, when administered in 
adequate amounts, confer a health benefit on the host” (microbial, viable and 
beneficial cells to health) [61,62]. The microbial genera more frequently used as 
probiotics are included into the LAB and related groups of microorganisms, such as 
Lactobacillus, some species of Streptococcus and Bifidobacterium. These 
microorganisms are considered as GRAS (Generally Regarded as Safe), many of them 
are also designed as Food Grade Microorganisms (FGM) and included in the Qualified 
Presumption of Safety (QPS) approach by the European Food Safety Authority (EFSA) 
for their use and safety in foods [63].  
On the other hand, the term prebiotic includes “a selectively fermented 
ingredient that produces specific changes, consumption or activity of the 
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gastrointestinal microbiota that confers benefits on host health” [64,65], whereas 
synergistic combinations of probiotics and prebiotics are called symbiotics. Among the 
carbohydrates qualified as prebiotics, fructo-oligosaccharides and gluco-
oligosaccharides are of main interest [65]. Despite the prebiotics definition refers to 
gastrointestinal use, this molecules are also used in vaginal products (e.g., in EcoVag® 
vaginal capsules, Bifodan A/S, Denmark) [66]. In the urogenital tract, the prebiotics 
could stimulate the growth of a limited number of potentially health promoting 
endogenous microorganisms, thus modulating the composition of the natural ecosystem 
[67]. Through in vitro assays, Rousseau et al. [67] have shown that the prebiotics 
affected the growth of vaginal lactobacilli, but inhibited some specific pathogens. 
There was a high emergence of papers published during the last 30 years, 
together with the constitution of scientific associations related with this subject, as the 
International Scientific Association for Probiotics and Prebiotics (ISAPP) and the 
participation of some international non-government associations, as Food and 
Agriculture Organization of the United Nations (FAO), World Health Organization 
(WHO), EFSA, National Food Commission (CONAL) in Argentina 
(http://www.alimentosargentinos.gov.ar/contenido/marco/CAA/capitulospdf/Capitulo_
XVII.pdf) that are working on the redefinition or in the correct use of some specific 
terms and the legal requirements for probiotics/prebiotics in each country or region [61-
63,65,68]. 
The term pharmabiotic has arisen related to the probiotic concept, and it includes 
“live or dead microorganisms, and some other microbial components or metabolites 
able to interact beneficially with the host” [69]. On the other hand, some other active 
compounds such as vitamins, peptides or proteins, hormones, growth factors, vegetal 
extracts or phytoderivatives could be included in formulations to complement the 
probiotic effect [70-73].  
The probiogenomic meaning genomic-based studies is beginning to provide 
insights into how probiotic bacteria sense and adapt to each tract environment [74]. This 
approach helps in the elucidation and understanding of the molecular basis of probiotic 
effects. The term metagenomic was also lately included to mean the carriage of 
metabolic pathways that are stable among individuals, and ethnic/racial background 
proved to be one of the strongest associations of both pathways and microbes with 
clinical metadata [23,75].  
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3.3. Clinical studies of urogenital probiotics 
Supported by the concepts described before and by the tendency to apply 
preventive politics around the world, the use of probiotics for urogenital applications has 
increased in the last years. One of the requirements for the design of a vaginal probiotic 
product or formula is to perform clinical assays to determine its safety (absence of 
adverse effects), efficacy and effectiveness in the clinical application proposed 
[61,62,64,65].  
Up to date, numerous clinical studies have been performed to evaluate the effects 
of probiotic or potential probiotic microorganisms on the urogenital tract of women 
under different physiological conditions: fertile, non-pregnant women (Table 1), 
pregnant women (Table 2) and post-menopausal women (Table 3). Moreover, several 
pathological conditions were considered, as shown in Tables 1-3. In this review, most of 
the available clinical trials that were published between 2009 and 2014 were included, 
because a deep analysis of trials published between 1991 and 2008 was previously 
reported [76]. 
In reproductive age, non pregnant women (Table 1), the use of probiotic or 
potential probiotic strains was evaluated mainly in three ways: 1) as a simultaneous 
treatment to antimicrobial drugs employed to treat BV and VVC, 2) as a subsequent 
treatment to antimicrobial drugs used to treat and/or prevent BV, CVV and UTI, and 3) 
as a single therapy to improve the vaginal ecosystem status and to treat and/or prevent 
BV, CVV, aerobic vaginitis (AV) and trichomoniasis [66,77-94]. In most of the studies, 
commercial probiotic products or new potential probiotic formulations were vaginally 
administered. Oral probiotic administration is considered an alternative route, believing 
that microorganisms can ascend to the vaginal tract after their excretion from the rectum 
[12]. Regardless of the administration method and of the strain assayed (referred as 
active pharmaceutical ingredient (API)), most of the clinical studies reported promising 
results by application of probiotics in the urogenital tract, such as higher cure rates and 
lower recurrences mainly in patients with BV, restoration of vaginal ecosystem balance, 
colonization of probiotic microorganism (in those cases where it was determined) and 
absence of serious adverse effects.  
With respect to probiotic uses in pregnant women (Table 2), which was mainly 
carried out by oral administration, clinical trials have evidenced positive results on the 
modulation of the vaginal microbiota (an increase of beneficial microorganism 
populations and a decrease of pathogenic microorganisms) [95-98]. The prophylaxis and 
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treatment of BV are of main relevance in pregnant women, because they have potential 
implications in preventing preterm birth associated to this pathology. Recent results 
suggest that the dominance of only L. iners in early pregnancy of healthy women might 
be associated with preterm delivery [43]. Oral probiotics were not effective to prevent 
spontaneous preterm delivery associated with BV [99], while the addition of vaginal 
probiotic to ampicillin prolonged the latency period in patients with preterm premature 
rupture of membranes (PPROM) remote remote from term [100]. 
Some clinical assays were carried-out in post-menopausal women in whom the 
menopause was natural or after a surgery (Table 3) [101-105]. Treatments with vaginal 
probiotics were proved effective to prevent recurrent BV and to positively modify the 
vaginal microbiome in small groups of patients [102,103], but oral probiotics failed to 
prevent recurrent urinary tract infections [101]. On the other hand, the local application 
of Lactobacillus acidophilus KS400 combined with estriol caused resolution or 
improvement of vaginal atrophy and normalization of the vaginal ecosystem in post-
menopausal women, while no adverse events were reported [104]. 
In conclusion, certain probiotic or potential probiotic strains, alone, combined or 
supplemented to antimicrobial drugs, were effective for prevention and treatment of 
BV. However, there is insufficient clinical evidence on the efficacy of probiotics for the 
treatment of UTI, VVC and other urogenital infections and for the prevention of preterm 
birth and its complications. More research in well-designed randomized controlled trials 
with larger patient size is needed. 
 
4. Profile of beneficial microorganisms and probiotic products 
When a probiotic/pharmabiotic product for the urogenital tract is going to be 
designed, several specific criteria should be considered (Figure 1). Some of the selection 
criteria, mainly those highly related with the demonstration of the mechanisms of action 
of specific strains in both in vitro and in vivo experimental models, will be described in 
the following items.  
 
4.1. Host specificity 
The microbial species show the phenomena of species-specificity and host-
specificity, evidenced by different scientists from a long time ago [106]. Some results 
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revealed that strains have distinctly evolved and have distinct genetic signatures 
between different human or animal hosts [8,10,15,75,107,108]. 
In this way, those strains isolated from the same host and mucosal environment 
where they will be applied are microorganisms with higher possibilities to colonize, 
survive and maintain in a specific site, and to exert then a specific physiological effect 
on the host. Based on the host-specificity and on the predominance of the vaginal LAB, 
the isolation of lactobacilli from vaginal tract of mice was performed, in order to study 
them in a specific experimental animal model [109,110]. Different vaginal lactobacilli 
were isolated from healthy women, to develop novel probiotic/pharmabiotic formula for 
the restoration of the human urogenital microbiome [21,111-116]. The phenotypic and 
genetic identification was performed by applying different methodologies that allowed 
the correct classification of Lactobacillus species [111-118].  
 
4.2. LAB functional genomic. Specific genes  
A variety of functional genomics approaches have been reported in the last years 
relating LAB associated to different sites of the human body [1,2,10,11,15]. In the case 
of some vaginal LAB strains, studies on specific genes [24,28,115,119] and the whole-
genome sequencing [113,114,120,121] were recently available. 
In the vaginal tract, each microbial species may harbor genes that relate to 
unique adaptation signatures and allow their persistence and colonization regardless of 
the presence of other LAB members [15,28]. Several genomes of vaginal LAB species 
evaluated were significantly smaller and had significantly lower G+C content than those 
of the non-vaginal species, suggesting a loss of non-essential genes towards a vaginal 
adaptation [9,15,28]. No protein families were found to be specific to the vaginal 
species analyzed, but some were either over- or under-represented relative to non-
vaginal species. Within the vaginal species, each genome coded for species-specific 
protein families [28]. As example, Macklaim et al. [114] described the whole-genome 
sequence of vaginal L. iners AB-1, showing an organism depleted of many metabolic 
pathways and that could have lost a high amount of genes. Moreover, L. iners seems to 
have undergone the horizontal acquisition of genes for survival in the vaginal 
environment, such as an iron-sulfur cluster assembly system, and several unique σ 
factors to regulate gene transcription in this fluctuating ecological niche. L. iners AB-1 
showed be equipped with predicted fibronectin (Fn)-binding adhesins. Subsequent 
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phenotypic studies evidenced the ability of L iners AB-1 to bind immobilized Fn, which 
can be a mechanism of vaginal persistence of the microorganism [122]. 
Genome sequence of Lactobacillus pentosus KCA1, a vaginal isolate from a 
healthy premenopausal Nigerian woman, allowed an improved understanding of 
metabolic systems within lactobacilli and suggested the metabolic versatility of the 
microorganism assayed [120]. Their results evidenced: a) loci encoding additional 
putative mannose phosphotransferase systems, b) clusters of genes for utilization of 
hydantoin, isopropylmalate, malonate, rhamnosides, and genes for assimilation of 
polyglycans, c) loci encoding putative phage defense systems including clustered 
regularly interspaced short palindromic repeats (CRISPRs), abortive infection (Abi) 
systems and toxin-antitoxin systems (TA), d) a putative cluster of genes for biosynthesis 
of a cyclic bacteriocin precursor, among other genetic features, which support the 
specific versatility.  
The draft genome of human vaginal L. plantarum CMPG5300 was recently 
reported, and a further detailed genome analysis could aid in identifying the factors 
implicated in adhesive properties of the strain [121]. In mutants of L. plantarum 
CMPG5300, the relevant role of sortase SrtA on auto-aggregation and adhesion abilities 
was evidenced [115]. Sortase SrtA is an enzyme that covalently anchors sortase-
dependent proteins (SDPs) to the cell surface, which could promote bacterial adhesion 
to host cells in the vaginal niche. 
In several potential probiotic vaginal L. gasseri, L. reuteri and L. rhmanosus 
strains, the presence of genes encoding sortases, pilin subunits and surface proteins, 
which could be involved in adhesion and colonization, were evaluated [119]. In L. 
reuteri CRL (Centro de Referencia para Lactobacilos Culture Collection) 1324 and 
CRL 1327, the genes encoding three adhesion proteins (mapA: mucus adhesion 
promoting protein, mubI: mucus-binding proteins, and cmbA: mucus- binding protein 
A) were identified. In L. rhamnosus CRL 1332, pilus-encoding genes were detected. In 
three L. rhamnosus strains assayed, two genes encoding for other surface proteins 
related to adhesion and biofilm formation were detected. 
In summary, the functional genomic has a relevant role in the selection process 
for potential probiotic microorganisms as it enables in silico the analysis of key 
genotypes involved in the mechanisms of probiotic activity [123,124]. Moreover, 
integrated genomic techniques could allow an increased knowledge on niche-related 
microbial characteristics, which contribute to colonization and to complex, beneficial 
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interaction between probiotic strains and their host [114,123]. Anyway, the genomic 
and experimental evidence supporting the use of a specific strain in probiotic 
applications must be demonstrated by clinical trials [61-63,123]. 
 
4.3. Beneficial properties of probiotics for the urogenital tract  
The beneficial roles of LAB in preserving a healthy vagina, preventing the 
infectivity and/or proliferation of pathogenic bacteria include the maintenance of acidic 
vaginal pH (lactic acid production), the protection from infections by products of 
endogenous bacteria as bacteriocins, hydrogen peroxide, and also by signaling to the 
host through activation of local innate and acquired immunity [76,125]. 
 
4.3.1. Adhesion properties 
The female genital tract (FGT) consists of two different types of mucosal 
surfaces [126]. The lower genital tract (ectocervix and vagina) is a type II mucosal 
surface, with a stratified epithelium. In contrast, the upper female genital tract (oviducts, 
ovaries, uterus, and endocervix) consists on a type I mucosal surface, being 
monolayered as most of the epithelia. It was long believed that the upper FGT was 
sterile, but recent studies have shown that there is a constant exposure to antigenic 
material (mainly commensal bacteria), which is transported to the uterine lumen by 
peristaltic waves [127]. The layer of mucus bound the epithelia is formed from a 
continuous gel matrix composed primarily of complex glycoproteins that acts as a 
barrier to protect the host from harmful antigens and promote luminal motility [128]. 
The layer of mucus is the first physical barrier to host-cell interaction by 
bacteria. Adhesion to this mucus is therefore the first step required for probiotic or 
beneficial organisms to interact with host cells and elicit any particular response [129]. 
Once administered, the bacteria should be adhered to the mucosal surface, either mucus 
or to the eukaryotic cell as a first step in the permanence or colonization of the host. A 
wide variety of specific and non-specific adhesins, such as proteins, lipoteichoic acid, S 
layers and polysaccharides of the bacterial surface can be involved in specific and non-
specific adhesion to host cells [130]. The structures of eukaryotic host cells, e.g., the 
double lipid layer-cell membrane, the mucus components (glycolipids) and the 
connective or basal membrane constituents (collagen, fibronectin, laminin, 
proteoglucanes) are also involved in colonization [119,122]. 
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Martín et al. [131] evidenced that there is a strong interaction between vaginal 
Lactobacillus salivarius Lv72 with glycosaminoglycans present on the surface of HeLa 
epithelial vaginal cell line, mediated by a soluble binding protein on the ABC 
transporter system. These data suggest that glycosaminoglycans play a fundamental role 
in attachment of mutualistic bacteria to the epithelium that lines the cavities where the 
normal microbiota thrives, OppA being a bacterial adhesin involved in the process 
[131]. In some vaginal or intestinal lactobacilli, a collagen A-binding precursor and 
aggregation-promoting factor-like proteins were suggested to participate on adhesion to 
Caco-2 and HeLa cells respectively; while a gliceraldehyde-3 phosphate dehydrogenase 
could explain the good adhesion of some strains to mucin [132].  
McMillan et al. [122] have shown that L. iners AB-1 bonded to immobilized 
fibronectin, and treating the bacterial cells with protease rendered the binding abilities 
to adhere to fibronectin to no functional, indicating the protein nature of the adhesion. 
In L. crispatus 2029, a vaginal strain isolated from fertile, healthy women and selected 
as a probiotic candidate, external protein surface layers (S layers) that completely 
surrounds the cells were described. S layers of L. crispatus 2029 were responsible for its 
adhesion on the surface of cervicovaginal epithelial cells [133]. A probiotic L. 
rhamnosus strain (Lcr35), which shows antimicrobial activity against some vaginal-
associated pathogens, adhered in vitro to epithelial cells from the endocervix, ectocervix 
and vagina [134]. 
In human vaginal lactobacilli isolated from Argentinean women, the in vitro 
study of several surface characteristics, including adhesion to human scrapped vaginal 
epithelial cells and to mucin, was carried out [111,119,135]. These assays allowed the 
selection of several potential probiotic strains with higher possibilities to colonize the 
vaginal mucosa. 
 
4.3.2. Aggregation and biofilm formation 
Aggregation promoting factors are secreted proteins that have been associated 
with a diverse number of functional roles in lactobacilli, including self-aggregation, 
bridging of conjugal pairs, co-aggregation with other commensal or pathogenic bacteria, 
and maintenance of cell shape [136,137]. Bacterial self-aggregation is an interesting 
phenomenon that can promote adhesion to host cells and displacement of pathogens. 
Malik et al. [115] reported that a human vaginal isolate, L. plantarum strain 
CMPG5300, showed high auto-aggregative and adhesive capacity. The auto-
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aggregating and adhesive phenotype of L. plantarum strain CMPG5300 was related to a 
sortase SrtA present on the surface of this strain, as mentioned above. 
Co-aggregation is another suggested mechanism through which lactobacilli can 
exert their probiotic effect to create a hostile micro-environment around a pathogen 
[136,137]. It might enable to form a probiotic barrier that prevents colonization by 
pathogenic bacteria. Ekmekci et al. [138] have characterized the co-aggregation ability 
of vaginal lactobacilli with uropathogenic E.coli. Younes et al. [136] indicated that 
lactobacilli displaying strong adhesion forces resulted in significantly large co-
aggregates with virulent toxic shock syndrome toxin 1-producing Staphylococcus 
aureus strains. With antimicrobial options fading, it therewith becomes increasingly 
important to identify lactobacilli that bind strongly with pathogens. The auto-
aggregation ability of vaginal strains of different Lactobacillus species (i.e. L. gasseri, 
L. salivarius, L. rhamnosus and L. reuteri) and co-aggregation with some specific 
urogenital pathogens (i.e. Streptococcus agalactiae, S. aureus and Candida albicans) 
was assayed, defining that some specific protein structures were related with this 
phenomenon [119,139,140]. 
Several surface properties, such as adhesion, auto- and co-aggregation, could be 
related with the biofilm formation by different microorganisms on mucosal surfaces 
[137]. McMillan et al. [141] indicated that urogenital probiotic L. rhamnosus GR-1 
caused a marked decrease in cell density and increased cell death of biofilms formed by 
pathogens associated to BV. Thus, probiotic lactobacilli could interfere with an aberrant 
vaginal microbiota through the eradication of pathogenic biofilms. This biofilm 
formation, which could promote the colonization and persistence of beneficial strains in 
the vaginal tract, was evaluated in several vaginal Lactobacillus strains [112,115,119]. 
Martín et al. [112] reported that the ability to generate a biofilm was observed in most 
of the 45 strains of vaginal lactobacilli, which were isolated from healthy women, and 
mainly in three L. jensenii isolates. Leccese Terraf et al. [119,142] demonstrated that 
some potential probiotic L. reuteri and L. rhamnosus strains formed biofilm in culture 
media without Tween 80. On the other hand, Malik et al. [115] observed that L. 
plantarum CMPG5300 showed an exceptionally high biofilm-forming capacity 
compared to other vaginal Lactobacillus strains, and that its mutant in the srtA gene lost 
the ability to form biofilm under the assayed conditions.. 
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4.3.3. Enzymatic activities and production of biosurfactants 
Referred to enzymatic activities, vaginal lactobacilli can be affected by enzymes 
present in the healthy or non-healthy urogenital tract [143]. Probiotic LAB should be 
resistant to enzymes that could lead to their inactivation, such as prolidase and sialidase 
that are relevant enzymes in the pathogenesis of BV [144].On the other hand, Spear et 
al. [143] reported that several Lactobacillus isolates did not grow in glycogen, but have 
shown to grow in glycogen-breakdown products, including maltose, maltotriose, 
maltopentose, maltodextrins and glycogen treated with salivary α-amylase. A 
temperature-dependent glycogen-degrading activity was detected in genital fluids that 
correlates with levels of α-amylase. Treatment of glycogen with genital fluids resulted 
in production of maltose, maltotriose, and maltotetraose, the major products of α-
amylase digestion. These studies indicated that human α-amylase is present in the 
female lower genital tract and helped to elucidate how epithelial glycogen can support 
Lactobacillus colonization in the genital tract [143]. 
Matrix metalloproteinase (MMP-8) is an enzyme known to alter the integrity of 
the cervix [145]. Witkin et al. [145] indicated that concentrations of vaginal 
extracellular matrix metalloproteinase inducer (EMMPRIN) were influenced by 
members of the vaginal microbial community and concentrations of D- or L-lactic acid 
isomers in vaginal secretions. Elevated levels of D-lactic acid and the ratio of D- to L-
lactic acid influenced EMMPRIN concentrations as well as MMP-8 levels. Thus, 
isomers of lactic acid may function as signaling molecules that alter host gene 
expression and influence risk of infection-related preterm birth. 
There are some other products released by LAB, as biosurfactants, which are 
amphyphylic compounds with a high surface and emulsified activity that is accumulated 
on the interphase of two fluid phases with different degree of polarity and H bonds, 
decreasing thus the interfacial and surface tension [146]. Different properties have been 
related with biosurfactant production by microorganisms, including the increased 
solubility of non-soluble water compounds (hydrophobic), union and adhesion to heavy 
metals, cellular adhesion and aggregation, quorum sensing and biofilm formation, and 
antimicrobial and antiadhesive properties against urogenital pathogens [147,148].  
 
4.3.4. Production of antagonistic substances 
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The antimicrobial substances produced by LAB include mainly organic acids, 
hydrogen peroxide and bacteriocins [76].  
Lactic acid. Lactic acid at sufficiently acidic pH is a potent microbicide, and 
lactic acid produced by vaginal lactobacilli may help to protect against reproductive 
tract infections [149]. O’Hanlon et al. [149] demonstrated that women with vaginal 
microbiota dominated by lactobacilli had significantly more lactic acid-mediated 
protection against infections than commonly believed. Lactic acid is one of the main 
products of the fermentative pathway of lactobacilli. The acidification of the vagina 
comes from a nearly racemic mixture of D and L-isomers [145]. This lactic acid in 
physiological conditions inactivated BV-associated bacteria without affecting vaginal 
lactobacilli [149]. L-lactic acid showed a more potent HIV inactivation [150] or 
inhibition of Neisseria gonorrhea growth in anaerobic conditions [151]. The lactic acid 
levels have influenced on the extracellular matrix metalloproteinase inducer, as 
signaling molecules that alter the host gene expression [145]. Free glycogen in genital 
fluid is also associated with a genital microbiota dominated by Lactobacillus, as cited 
before, suggesting that glycogen is important for maintaining genital health. Treatments 
aimed at increasing genital free glycogen might impact Lactobacillus colonization, as 
suggested by Mirmonsef et al. [152]. 
Hydrogen peroxide. H2O2-producing Lactobacillus strains have been related 
some years ago to a healthy vaginal ecosystem, because H2O2 produced by vaginal 
lactobacilli was believed to protect against infection at that time [153].  
H2O2-producing lactobacilli inactivated pathogens in vitro in protein-free salt 
solution [154]. However, cervicovaginal fluid (CVF) and semen had significant H2O2-
blocking activity. Given the H2O2-blocking activity of CVF and semen, it is implausible 
that H2O2-production by vaginal lactobacilli is a significant mechanism of in vivo 
protection. Physiological concentrations of H2O2 produced no detectable inactivation of 
either BV-associated bacteria or vaginal lactobacilli [149]. Moreover, at very high 
concentrations, H2O2 was more toxic to vaginal lactobacilli than to BV-associated 
bacteria. On the basis of these in vitro observations, these authors concluded that lactic 
acid, not H2O2, is likely to suppress BV-associated bacteria in vivo. 
The results of Graver and Wade [151] have shown that there was no evidence of 
a specific mechanism of N. gonorrhoea inhibition other than acid production by vaginal 
lactobacilli, while hydrogen peroxide was not produced. The acidification potential of 
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vaginal lactobacilli under anaerobic conditions may be their most important 
characteristic conferring protection against N. gonorrhoeae infection. 
On the other side, Cadieux et al. [155] have shown that compounds secreted by 
lactobacilli likely protected the urogenital tract from uropathogenic Escherichia coli 
(UPEC) colonization and infection by inhibiting growth, inducing stress and down-
regulating proteins critical for host attachment.
 
In a dose- and pH- dependent manner, 
lactic acid, hydrogen peroxide and Lactobacillus supernatants all strongly inhibited 
UPEC C1212 growth and increased the promoter activity of outer membrane proteins 
(OMPs) A and X, two porins normally up-regulated in response to UPEC membrane 
stress. Lactic acid and the culture supernatants also down-regulated the promoter 
activity of the major subunits of type 1 and P fimbriae, critical adherence factors within 
the urogenital tract. The results of Atassi and Servin [156] indicated that in the presence 
of lactic acid at a concentration present in Lactobacillus supernatants, hydrogen 
peroxide displayed enhanced killing activity. Collectively, these results demonstrated 
for hydrogen peroxide-producing Lactobacillus strains that the main metabolites of 
Lactobacillus (lactic acid and hydrogen peroxide) act co-operatively to kill enteric, 
vaginosis-associated and uropathogenic pathogens. 
Bacteriocins and bacteriocin-like substances. There is an increased interest in 
the development of treatments using antimicrobial derived primarily from 
Lactobacillus, such as lactic acid described previously and ribosomally produced 
antimicrobial peptides (bacteriocins) [157]. These substances effectively inhibit 
pathogenic bacteria, are safe and do not possess any threat to healthy vaginal microbiota 
[73,116,157-163]. Different bacteriocins have been published from strains isolated from 
the vaginal tract. Lactocin 160, produced by a vaginal L. rhamnosus [158] and a 
subtilosin, produced by a Bacillus amyloliquefaciens strain, were active against 
bacterial vaginosis associated pathogens, combined with glycerol monolaurate, lauric 
arginate, Y-poly-L-lysine, lauramide arginine ethyl ester [159,161]. The molecular 
mechanisms of action of lactocin 160 was evaluated, revealing that this compound 
targets the cytoplasmic membrane of G. vaginalis, causing the efflux of ATP molecules 
and dissipation of the proton motive force [158]. Zinc lactate and sapindin act 
synergistically with lactocin 160 against this pathogen and therefore have a potential to 
be successfully used as the components of the multiple-hurdle antimicrobial formulation 
for the treatment of BV [160].  
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Lactobacilli isolated from the human vaginal tract in Tucumán, Argentina, were 
screened for the production of antagonistic substances, lactic acid, hydrogen peroxide 
and bacteriocins against a wide variety of pathogenic microorganisms [164,165]. In 
those studies, L. salivarius CRL 1328 produced salivaricin CRL 1328, the first 
bacteriocin described from a vaginal isolate, showing antimicrobial properties against 
urogenital pathogens [166]. The complete biosynthetic cluster of salivaricin CRL 1328 
was identified, and this bacteriocin was characterized as a class IIb two-peptide 
component [167]. Salivaricin CRL 1328 was shown to dissipate membrane potential 
and the transmembrane proton gradient of pathogenic Enterococcus faecalis MP97 cells 
[167].  
Sabia et al. [116] have described a bacteriocin-like substance produced by L. 
fermentum CS57 from vaginal origin. Also, Pediococcus pentosaceum SB83, with 
bacteriocinogenic activity against Listeria monocytogenes and able to survive in 
simulated vaginal fluid, was indicated as a safe strain for probiotic vaginal use [162]. 
Stoyancheva et al. [163] have shown the presence of gasserin A operon in some of the 
vaginal strains with bactericidal effect.  
Referred to in vivo effect of bacteriocins, nisin was studied as a anticonceptive 
agent and administered in high doses to animal experimental models without production 
of adverse effects [168]. In vivo and in vitro assays indicated that lactocin 160 did not 
produce irritation on the vaginal epithelia [169]. However, in vivo studies on 
bacteriocins that could be effective in the prevention of infections on the urogenital tract 
have not yet been reported, but only in some other tracts [170].  
 
4.3.5. Competition by nutrients 
The competition by nutrients provides a selective advantage for those 
microorganisms that can use them first and selectively, for their own growth and 
survival [76,171]. The main evidence of this phenomenon at the urogenital tract is the 
preferential use of glycogen, or some of other metabolic products release to this 
environment, by the endogenous vaginal LAB, as cited before [143]. 
 
4.3.6. Inhibition of pathogen colonization: animal experimental model  
Different animal experimental models has been set up to evaluate the probiotic 
effect at the urogenital tract and the protection against pathogens, either to go further 
into the mechanisms of action or to explain the preventive/protective effect [172,173]. 
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The most frequent animal used was mice, but also rabbit [157,169]) or macaque was 
used trying to simulate the situations of the human tracts [174].  
Some years ago, a murine experimental model was setup to evaluate 
colonization in the urinary tract of a murine selected L. fermentum strain, after its 
inoculation (included in agarose beads) into the urethra of female mice [109]. Reduction 
of uropathogenic E. coli viable cells was observed after a prophylactic or therapeutic 
protocol with the L. fermentum strain assayed [175]. Hormonal treatment with estradiol 
and lactobacilli has shown to protect animals against challenge with E. coli [110]. In 
mice treated with amoxicillin, which is known to promote colonization of E. coli and 
reduce adherence of the normal vaginal microbiota, L. fermentum showed an inhibitory 
effect against UTI. Lymphocytic proliferation at the submucosal level was observed in 
E. coli-challenged animals while no histological modifications were associated with L. 
fermentum [176].  
On the other hand, colonization of mouse vagina by inoculation of human 
vaginal potentially probiotic lactobacilli was also assayed. Different rates of 
colonization were obtained depending on the particular strain tested [177,178]. At 
cytological or histological levels, lactobacilli did not cause adverse effects in the murine 
vaginal tract. The intravaginal administration of L. salivarius CRL 1328 and L. gasseri 
CRL 1263 did not affect the amounts of granulocytes and macrophages present in 
vaginal washings, evaluated by flow cytometry [140]. Zárate et al. [179] demonstrated 
that, while the inoculation of S. aureus produced a remarkable inflammatory response 
and structural alterations in the vaginal mucosa, they decreased significantly when the 
mice were protected with L. paracasei CRL 1289. Recently, the preventive effect of L. 
reuteri CRL 1324 against vaginal challenge with Streptocccus agalactiae was 
demonstrated in the experimental murine model [140]. 
 
4.3.7. Immune system modulation  
The female genital tract is equipped to deal with a variety of foreign substances 
including spermatozoa, a fetus that is immunologically distinct from its mother, and a 
wide array of pathogens. These pathogens include viruses, bacteria, fungi and parasites 
[14,108,126,180,181]. To add to this complexity, the various parts of the female genital 
tract are influenced by sex hormones during menstruation [182]. All of these 
components act in concert to optimize the conditions for reproduction and a successful 
pregnancy [108,126,180-184]. The female genital tract is protected against these various 
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invaders by two inter-related mechanisms: the innate and the adaptive immune systems. 
The intricate interplay between the two arms of the immune system, plus their 
interaction with the genital tract bacterial microbiota and the host epithelial cells, are 
ultimately responsible for the health of the lower female genital tract [181-184].   
There are several layers of innate protection in the lower female genital tract. 
The epithelial cells covering the length of the female genital tract act as the first line of 
defense and a physical barrier by inhibiting the passage of pathogens and their 
associated particles [126,181]. It has been suggested that there is a site-specific mucosal 
immune system in the female upper genital tract that differs from that described in the 
gastrointestinal and respiratory tracts [185,186]. Furthermore, the immune system in the 
upper genital tract differs from that of the lower genital tract [14, 180-186]. The putative 
immune system in the upper genital tract appears to contribute to the maintenance of an 
aseptic milieu; that is, this immune system inhibits the growth of microorganisms that 
sporadically colonize this region [181,183]. 
In contrast, the lower genital tract is constantly exposed to microorganisms, 
including species of commensal as well as pathogenic organisms [184].  The mucosal 
components of the lower genital tracts have adapted to a dynamic, nonsterile 
environment challenged by a variety of antigenic/inflammatory stimuli associated with 
sexual intercourse and endogenous vaginal microbiota [184,187]. Clearly, it is essential 
that these mucosal tissues develop mechanisms for selectively respond to pathogens, 
while simultaneously avoid chronic inflammation due to immune responses to 
commensal microorganisms.  
Innate immune system. The innate immune system in the female genital tract is 
highly complex and multifactorial. Mucosal epithelial cells, fibroblasts, lymphocytes, 
macrophages and dendritic cells associated with the female genital tract have evolved a 
unique mechanism for the recognition of pathogens [187]. These cells express a variety 
of Toll-like receptors (TLRs), allowing them to recognize the different repertoire of a 
wide range of molecular patterns associated with pathogens (PAMPs) [187,188]. TLRs 
recognize conserved PAMPs synthesized by microorganisms including bacteria, fungi, 
parasites, and viruses as well as endogenous ligands associated with cell damage. It is 
likely that TLR distribution in the female genital tract reflects an immunological 
tolerance of commensal organisms in the lower portions of the tract (i.e., vagina, 
ectocervix, and to some extent, the endocervix), as well as an intolerance of commensal 
microbiome in the upper portion of the tract (i.e., the endometrium and fallopian tubes) 
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[184]. The mucosal surface of the upper portion of the female genital tract is generally 
considered a sterile site, in part due to the cervical mucus, which filters bacteria and 
other debris. However, this barrier can readily be crossed by a variety of infectious 
agents, typically leading to endometritis and salpingitis [181,182]. Thus, it is essential 
that the upper genital tract epithelium has the capacity to recognize and respond to 
ascending pathogens while simultaneously avoiding a state of unnecessary 
inflammation that might disrupt the epithelial barrier. The sequelae of such 
inflammation in the upper genital tract would be highly detrimental to the defense and 
reproductive functions of the mucosal surface [184]. If the luminal epithelial barrier is 
broken by acute inflammation, damaged epithelial cells initiate and coordinate the 
inflammatory response, alerting adjacent epithelium and underlying immune cells of the 
potential danger posed by various microorganisms [184]. 
Vaginal epithelial cells produce several compounds with anti-microbial activity, 
some of them identified as antimicrobial peptides (AMP) synthesized and secreted also 
by different cell types related with the innate immunity and defensins that are 
microbicidal per se. They also produce mucus, which covers the internal surface of the 
vagina and cervix and serves to trap infectious agents [129,154]. The epithelial cells 
further help protect against pathogens by expressing several receptors as cited, including 
a number of TLRs, MD-2, as well as major histocompatibility complex (MHC) 
molecules [181,182,189]. These molecules help recognize process and initiate cellular 
immune responses to obliterate pathogens. When activated, epithelial cells can also 
produce a variety of cytokines and chemokines such as TNFα, G-CSF, GM-CSF, IL-6 
and IL-8, to help recruit immune cells, induce their differentiation/activation and 
develop successful immune responses, indicating thus how the epithelial function is 
related also with the immune system [181].  
If the protection afforded by the epithelial barrier is compromised, however, 
pathogens encounter a second layer of innate defense consisting of specialized immune 
cells and their products [180,181]. These cells, which include macrophages, dendritic 
cells, neutrophils, and natural killer cells, are dispersed throughout the female genital 
tract, surveying that environment [181]. 
Innate immunity is critical for controlling the first stages of infection, but the 
activity of dendritic cells (pDCs) and Natural Killer (NK) cells may not be sufficient for 
complete microbial clearance and therefore, the activation of adaptive immunity is 
fundamental for full protection, as DCs are key players in connecting the innate and 
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adaptive immunity [190-193]. In the FGT, as described for other mucosal sites, 
macrophages and DCs are the principal antigen presenting cells (APCs). Under normal 
conditions, the main populations found in the FGT mucosa are Langerhans cells located 
within the epithelium and submucosal DCs located beneath the epithelium [193,194] ] 
In the steady state, Langerhans cells and submucosal DCs are highly phagocytic 
and express several pattern recognition receptors (PRRs) that can recognize a wide array 
of microorganisms. After pathogen recognition through PRRs, DCs and Langerhans 
cells undergo a programmed maturation and migrate to the draining lymph nodes to 
prime naive T and B cells. Both cells are tolerogenic in the absence of pathogens [193]. 
In case of infection, or in an inflammatory state, other blood-derived populations of 
APCs such as pDCs and monocyte-derived DCs can also be found in the FGT mucosa 
after pathogen challenge. The current paradigm of immune induction to infectious 
agents at body surfaces covered by squamous epithelium such as the vagina is that 
Langerhans cells encounter pathogens within the epithelium, take up antigens from 
pathogens, and migrate to the draining lymph nodes to prime naive T cells [184]. 
Therefore, some observations suggest that Langerhans cells provide critical 
antimicrobial defense functions and suggest that treatments to augment their activity 
may be useful therapeutic tools [193].  
Specific or adaptative immune response. Then, an antigen-specific attack is 
launched by the adaptive arm of the immune system, consisting of T and B cells, after 
the microbial antigens have been recognized, processed and presented by antigen 
presenting cells [181,190,191]. The cross-talk between the innate and the adaptive 
immune systems, as well as the important role that T and B cells play in conferring 
long-term immunity in the genital tract, have been discussed previously [181,183,195]. 
The humoral immune compartment of the human genital tract exhibits features 
which are unique and functionally different from other compartments of the mucosal 
immune system [181,190,191,194]. The main immunoglobulin (Ig) isotype found in the 
lumen of the upper FGT is IgA as in other mucosal tissues [185]. This is not the case for 
vagina and ectocervix, where the main Ig isotype present in cervicovaginal secretions is 
IgG [195,196]. These differences are related to the transcytosis and the presence or 
absence of the corresponding Fc receptors, which allow the transport of the respective 
Ig across epithelial cells [181]. To add complexity to the humoral immune system in the 
FGT, it was reported that hormonally mediated variations modulate the expression of 
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receptors on epithelial cells involved in Ig transport and profoundly influence Ig levels 
in the vaginal fluid [183]. 
Although neutralizing antibodies are protective against infections with many 
microorganisms, induction of T cell mediated immunity, particularly antigen-specific 
CD4+ Th1 cells, is critical for full protection in specific infections [181]. Th1 cell-
mediated immunity is indispensable for the destruction of intracellular pathogens and is 
driven primarily by T lymphocytes [197]. T cells are located in the stroma of the vagina, 
cervix and uterus both below the epithelium and also dispersed within epithelial cells 
where they are known as intraepithelial lymphocytes [181].  
CD4+ T cells assist CD8+ T cells in their migration to vaginal mucosa by 
secreting recruiting cytokines and they are the main producers of IFN-γ, a pleiotropic 
cytokine, and exert its/their? powerful effect by several mechanisms [197]. On the other 
hand, CD8+ cytotoxic effector T cells recognize virus infected cells through peptide-
bound MHC class I molecules expressed on their surface, inducing apoptosis through 
perforin- and granzyme-mediated cytolysis or inducing apoptosis infected cells Fas-
ligand [198]. Thus, a CD4+ and CD8+ balance is needed for controlling infection, being 
CD4+T cells more important at the earlier stages of infection and CD8+T cells 
becoming more important later [199].  
More recently, it has been described that Th17 are present at mucosal surfaces 
and are thought to play a role in maintenance of immune homeostasis discriminating 
autochthonous microbiota from pathogens [200]. They have been involved in responses 
to fungi and bacteria at mucosal sites, and only very recently they have been studied in 
the context of different type of infections [201]. 
Vaginal lactobacilli and immune system: There are specific studies performed 
with some strains that have shown strain-related effects on the innate or specific 
immune system, and also dealing with the signalling, that will be indicated as follows:  
Lactobacilli help to a healthy vagina by producing several factors including 
lactic acid, as assessed by Mirmonsef et al. [184] who described the dramatic effects of 
TLR ligands and short chain fatty acids produced by bacteria microbiota on immune 
function. 
L. crispatus 2029 induced NF-kB activation in epithelial cells and did not induce 
expression of innate immune mediators IL-8, IL-1B, IL-1a and TNF-a. It inhibited IL-8 
in epithelial cells and increased production of anti-inflammatory cytokine IL-8 [133]. 
This specific strain, a H202 producer, presented antagonistic spectrum and a S-layer 
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responsible for its adhesion on the surface of cervicovaginal epithelial cells and on type 
IV collagen (a major molecular component of epithelial cell extracellular matrix), did 
not cause toxicity, epithelial damage and apoptosis, and showed a recognition by TLR 
2/6 [133] 
Li et al. [202] have shown that L. reuteri RC-14, a human vaginal isolate, 
produced small signaling molecules that were able to interfere with the staphylococcal 
quorum-sensing system agr (a key regulator of virulence genes) and repress the 
expression of toxic shock syndrome toxin-1 (TSST-1) in S. aureus MN8, a prototype of 
menstrual TSS S. aureus strains. 
L. rhamnosus GR-1 enhanced the activation of NF-κB and TNF release through 
increased levels of TLR4 on the bladder cells and altered subsequent release of 
cytokines from urothelial cells. By influencing immunological factors as TLR4, that is 
fundamental in the process of fighting pathogens, probiotic could facilitate pathogen 
recognition and infection clearance [203]  
L. helveticus HY7801 inhibited the expression of pro-inflammatory cytokines 
including TNF-a, IL-1B and IL-6, and inflammatory enzymes COX-2 and INOS, as 
well as the activations of NF-kB in Candida infections. Moreover, L. helveticus 
HY7801 caused an increase in IL-10 cytokine expression in the vaginal tissues [173]. 
Wagner and Johnson [204] suggested that that C. albicans infection induced pro-
inflammatory responses in vaginal epithelial cells, and L. rhamnosus GR-1 and 
estrogens suppressed expression of NF-κB-related inflammatory genes. Lactobacilli 
could modify epithelial cell cytokine production (e.g. inducing IL-1α and IL-1β 
expression) by activation of alternate signal transduction pathway (as MAPK/AP-1), 
which could be mechanisms for probiotic modulation of morbidity in vulvovaginal 
candidiasis. 
Rizzo et al. [205] have shown that Lactobacillus crispatus ATCC 33820 
influenced the innate immune response of HeLa epithelial cells to C. albicans infections 
through the involvement of TLR2/4, IL-8 and human B-defensin 2 and 3.  
Evrard et al. [206] have demonstrated the dose-dependent immunomodulation of 
human dendritic cells by L. rhamnosus Lcr35. The strain, in high doses, increased the 
pro-Th1/Th17 cytokine levels (TNFa, IL-1B, IL-12p70, IL-12p40, and IL-23), but only 
caused a low increase in IL-10 concentration, indicating a semi-maturation of the cells, 
and a tendency to a pro-inflammatory effect. On the contrary, other authors [207,208] 
have suggested that L. rhamnosus affected macrophages-dendritic cells interaction 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
27 
 
through a granulocyte colony-stimulating factor (G-CSF) modulation directed to the IL-
12/23 p40 response of the dendritic cells. 
Is important to point out also that vaginal microbiota affects the fetus [209-211]. 
Stencel-Gabriel et al. [209] have shown that lactobacilli in vagina affected the 
development of the neonatal immune system, because they have detected different 
degree of expression of CD45RO on neonatal CD4+Tcells and IL 12 production in 
CBMC (cord blood mononuclear cells) culture). On the other side, Bloise et al. [210] 
have evidenced, the in vitro effect of heat killed Lactobacillus rhamnosus GG (LGG) on 
primary trophoblast cells purified from normal human term placenta. LGG stimulated 
IL-4, IL-10 and urocortin release, while inhibited LPS-induced TNF-α release, 
suggesting an immunomodulatory effect in human placenta. These effects did not alter 
the basic trophoblast functions. The immunomodulatory effect of L. rhmanosus GR-1 
on human placental trophoblast cells was evidenced by Yeganegi et al. [211], showing 
the activation of the Janus Kinases/Signal Transducers and Activators of Transcription 
(JAK/STAT) and mitogen-activated protein kinase (MAPK) pathways. 
The described results indicate/suggest the signaling and the immunomodulatory 
effect of some specific Lactobacillus strains on the human female urogenital tract. 
Eventhough the upper tract is sterile, some of the cited studies have isolated DNA of 
some vaginal strains from placenta after the delivery [54,56]. These new evidences 
indicate how the indigenous microbiota or microbiome interacts with the different cells 
of the human urogenital tract, supported also by the hematogenous transfer of the 
microbiota from different tracts [54]. 
 
4.4. Compatibility of strains, safety and resistance to the environmental conditions 
Once the potential probiotic strains are selected, based on the production of 
primary or secondary metabolites (antagonistic substances, biosurfactants) and surface 
properties (auto- and co-aggregation, biofilm formation and adhesion to eukaryotic cells 
or tissue components), some other studies need to be performed (Figure 1). As the 
beneficial properties are specifically related with a particular strain, the combination of 
strains in a multi-strain probiotic product is an interesting strategy looking for a 
synergistic effect [73,212]. In this sense, the first assay to be carried out is the 
compatibility between the beneficial strains [118].  
Once selected the compatible strains, their safety characteristics must be 
assayed, according to recommendations of the regulatory agencies [61,64,68]. 
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Eventhough the LAB are considered as GRAS, QPS and FGM [63], they must be 
assayed in some specific properties of safety, as follows: 
Resistance to antibiotics. LAB are intrinsically resistant to vancomycin, but they 
shouldn´t carry plasmids or extrachromosal elements that could transfer the antibiotic 
resistance, either horizontally or transversally [213-216]. The strains must be assayed by 
applying different methodologies, because there are not clear limits of the 
sensitivity/resistance to antibiotics in the LAB group, as in the pathogens case. Clinical 
and Laboratory Standards Institute (CLSI) and the Standard Operating Procedure (SOP) 
gave some type of indications on this topic, and also some documents were published 
by the EFSA for microorganisms included in product for human and animal 
consumption [68]. The antibiotic resistance of the strains must be assayed both by 
phenotypic experiments and at the genetic level, to determine if the resistance genes are 
present, either by an incomplete cluster, or because they are not expressed in the 
assayed conditions [61,62,215,216]. 
Production of enzymes related to deleterious effects. Hemolysins, gelatinases or 
collagenases could produce damage into the host. Enzymes evaluation must be carried 
out by using methods recommended by regulatory agencies [62,64,68]. 
Animal studies for evaluation of safety. Eventhough the safety definition of 
LAB, it is very valuable to determine if the beneficial strains do not produce damage, 
adverse or collateral effects on the host once administered by the specific way. In this 
sense, mice are one of the most frequent experimental animals used with this purpose 
[76,176,178,217], and also rabbits and macaque models described before in item 4.3.6. 
The animal studies also help in the understanding of the mechanistic effect of some 
specific strains. 
Referred to the resistance to the environmental conditions, if the strains are 
going to be administered locally at the urogenital tract, they must be assayed in their 
resistance to vaginal fluid and/or urine [218,219]. If they will be applied as oral capsule 
or foods, their survival must be studied in intestinal fluid or into their components, 
either in one phase assays, or in continuous models resembling the different areas of the 
intestinal tract [220-226].. The strains must survive under these conditions and express 
later their beneficial characteristics [219-226].  
 
4.5. Technological properties of urogenital probiotics 
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Microbial cells are API of the probiotic products for pharmaceutical applications. 
As shown in Figure 1, one of the main challenges during the design of probiotic products 
is the inclusion of a high number of viable and active microorganisms resisting to the 
conditions of manufacturing process and shelf life of products and later to the 
environment or target tract or mucosa [64]. 
Therefore, the technological characterization of potential beneficial 
microorganisms is a basic evaluation required to complement the strains selection, in 
order to determine if they can be included in the design of probiotic products that will 
be elaborated at large-scale and later commercialized [64]. These requirements are 
supported on results of research studies and guidelines established by scientific 
organizations [61,62,65], which proclaim that the efficacy of probiotics depends on the 
number of viable cells [10
6
-10
9
 CFU per doses of formulation] reaching their target. 
 
4.5.1. API optimal production for urogenital probiotics 
In pharmaceutical biotechnology, the development of suitable strategies for 
optimal API production for vaginal probiotic products is a fundamental aspect. 
However, these studies have scarcely been reported to date, which can be possibly due 
to intellectual protection of results or patent processes. The effect of the culture 
conditions on the growth and inhibitory metabolite production of several potential 
probiotic vaginal lactobacilli, which were isolated from human vagina in Tucumán, 
Argentina, was reported [165,227,228]. In the specific case of bacteriocin-producing L. 
salivarius CRL 1328, different physical and chemical factors (e.g. initial pH of the 
culture media, incubation temperature and growth medium components) drastically 
affected the biomass and bacteriocin production [227]. Both bacterial cells and 
bacteriocin of L. salivarius CRL 1328 are candidates to be included in a pharmabiotic 
product to prevent or treat female urogenital infections. Therefore, to optimize 
simultaneously the production of both biomass and bacteriocin, culture media of lower 
cost than conventional laboratory media were formulated [227]. 
In order to potentially apply the results obtained at laboratory scale to the 
technological production of potential probiotic microorganisms and metabolites for 
pharmaceutical products, alternative low-cost ingredients of culture media (e.g. whey 
permeate, potato extracts, molasses, soy milk, corn syrup, etc.) [229] and different 
strategies of fermentation and biomass production must be evaluated. As example, whey 
protein concentrate supplemented with different substances, such as yeast extract and 
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Tween 80, supported the optimal growth of potential probiotic vaginal lactobacilli 
(unpublished data). Recently, Donnarumma et al. [230] reported that the optimal growth 
of potential probiotic vaginal Lactobacillus crispatus L1 was obtained in a semidefined 
medium containing soy peptone and yeast extract as nitrogen sources and glucose as 
carbon source. In order to overcome the inhibition of L. crispatus L1 growth caused by 
lactic acid produced during the culture, an in situ product removal fermentation process 
using a bioreactor with microfiltration modules was evaluated. This strategy allowed a 
7-fold improvement of the L. crispatus L1 viable biomass yield compared to traditional 
batch processes.  
 
4.5.2. Storage of API of interest and formulation of urogenital probiotics 
Probiotic products with beneficial effects on the female urogenital tract can be 
mainly manufactured as solid, such as tablets, capsules and suppositories, among others, 
as mentioned in Tables 1-3. In these products, concentrated cultures of probiotic 
microorganisms must be included in matrixes with low water activity (aw). Potential 
probiotic strains should be compatible with the physical form and excipients of the final 
product and they should survive and maintain their beneficial properties during the 
storage of concentrated cultures and during the product shelf life [64,76]. 
The preservation of concentrated cultures can be carried out applying several 
methodologies, such as lyophilization, spray drying and microencapsulation [70,73]. 
However, the different steps of microbial preservation processes can cause structural and 
physiological cell damage through several mechanisms, affecting negatively the stability 
(viability and/or functionality) of microorganisms. Various factors such as water activity, 
pH, oxygen tension, temperature, osmotic pressure, intrinsic characteristics of strains, 
etc., affect the microbial survival during the preservation [231].  
The challenge in the development of vaginal probiotics is to found production and 
storage strategies allowing to obtain physiologically more robust strains, in which the 
loss of viability and functionality is limited [62,64]. For example, microbial pre-
adaptation at different temperatures or at different solute concentrations could increase 
the strain resistance to some stress conditions during drying and storage [232]. However, 
this type of studies was not published for vaginal probiotic microorganisms. 
Table 4 shows several technological studies carried out in different probiotic or 
potentially probiotic microorganisms for vaginal pharmaceutical products 
[70,73,212,231,233-242]. To the best of our knowledge, the resistance of vaginal 
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probiotic strains to spray drying has not yet been reported. The freeze-drying of 
Lactobacillus cultures, which could be incorporated into a suitable pharmaceutical form 
of vaginal application, has been proved successful to preserve the stability during the 
long-term storage of some potential probiotic strains [231,233]. The use of different 
protective compounds (carbohydrates and proteinaceous substances such as skim milk) 
improved the bacterial survival during the processes assayed [231,233].  
On the other hand, the microencapsulation of probiotic strains can provide a 
means to optimize the delivery and bacterial survival in the site of action [70,234]. This 
technology confers to probiotic cells a physical barrier against external conditions, 
potentially enhancing their stability during the storage and under adverse conditions of 
the tract where will be applied. Microencapsulation of freeze-dried or non dried cultures 
was evaluated in order to obtain particulate-delivery systems with bioadhesive properties 
for urogenital probiotic products [70,234]. However, survival of encapsulated bacteria 
during storage was not yet reported. 
Several studies describing the pharmaceutical formulation and/or API stability of 
potential vaginal probiotics were found in the literature (Table 4). The pharmaceutical 
forms assayed were: vaginal tablets (with and without retarding polymer), liquid systems 
such as vaginal gels and douches, vaginal capsules, ovules/suppositories and pod-
intravaginal rings. In most of the pharmaceutical formulations, except in liquid systems 
and in a type of vaginal tablets, the viability and/or biological characteristics (e.g. 
antimicrobial activity and survival in fluid vaginal) of microorganisms was maintained 
during manufacture and storage for different time periods. Muller et al. [233] determined 
the stability of freeze-dried powders and vaginal pharmaceutical formulations according 
to the ICH Guideline Q1A [243], which requires a minimum of 12 months to test 
products under different storage conditions; however, the stability studies can be 
performed up to the expiration date (24 or 36 months). In order to reduce the length of 
the stability assays and the costs of laboratory technology, different mathematical models 
were proposed to predict the bacterial viability during storage. 
Several excipients or active pharmaceutical ingredients of conventional vaginal 
products could complement the effects of probiotic microorganisms and enhance the 
benefits on the host, therefore being good candidates to be incorporated in the final 
formula. In this sense, Vera Pingitore et al. [73] designed urogenital pharmabiotics 
including beneficial strains combined with other ingredients of microbial origin (an 
antimicrobial metabolite) and substances with different functionalities (prebiotics, 
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vitamins, antioxidants). The compatibility of all the ingredients was carefully assayed, in 
order to preserve the API stability during the processes of production and long-time 
storage. 
 
4.5.3. Probiotic products for the urogenital tract 
According to the international requirements, a probiotic product must include the 
label describing the microbiological content, the name of the strains, the minimum 
numbers of viable bacteria at end of shelf-life, the storage conditions, and specific claims 
on their benefits on the host [61,62,65]. Tables 1-3 summarize the available information 
of probiotic or potential probiotic products (single- or multi-strain formulation, specific 
microbial strains, minimum numbers of viable cells, commercial name and manufacturer 
data) that were used in several clinical assays. 
Most of the probiotic strains for the female urogenital tract are included in 
pharmaceutical forms for vaginal administration, e.g. as capsules (EcoVag
®
, 
Gynophilus
®
, LACTIN-V and Probaclac Vaginal), tablets (Gynoflor
®
, ActiCand 30, 
Normogin
®
 and Florisia
TM
), pessaries or powders (LACTIN-V powder, with a vaginal 
applicator). Moreover, probiotic capsules (LaciBios
®
 femina, Lactogyn, prOVag
®
 and 
Provinorm) and tablets for oral administration are commercialized. Most of the products 
detailed in Tables 1-3 contain between 10
7
 and 10
9
 viable cells of freeze-dried 
microorganisms and require to be stored usually refrigerated. However, the technological 
characteristics of the strains and the details of the production process are not available in 
most of the cases.  
 
5. Concluding remarks 
Different Lactobacillus species are the predominant microorganisms in the 
healthy human vaginal microbiome. Numerous in vitro and in vivo studies have 
evaluated the beneficial characteristics suggested or involved in the protective 
mechanisms of lactic acid bacteria in the urogenital tract, but still there are many gaps in 
the area. Technological studies have scarcely been reported to date, because most of the 
probiotic strains or products are protected by patent processes or under the “confidential 
clauses” of the manufacturers or pharmaceutical companies. The current state of the 
application of probiotics for the urogenital tract in medical clinical practice and 
evidence of their effects must be demonstrated, mainly referred to the stability of the 
vaginal microbiome and to the protection/prevention of specific syndromes or 
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infections, both at the vaginal and urinary tract. The host genetic polymorphism lately 
described is being also related to the susceptibility to infections, and must also be 
considered. Urogenital probiotics were clinically evaluated employing different 
bacterial strains, doses, schemes of treatment, routes and vehicles of administration; 
therefore unique recommendations for their use are precluded. The potential benefits of 
probiotics on the health of women around the world strongly deserve to carry out 
further studies to complement the current knowledge and to support the clinical 
applications of probiotics in the urogenital tract, either as preventive or therapeutic 
agents. 
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Figure captions 
Figure 1. Steps in the selection of probiotic microorganisms for the human female 
urogenital tract (adapted from reference [64]). 
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Table 1. Effects of probiotic or potential probiotic microorganisms on the human urogenital tract: Clinical assays performed in fertile, non-pregnant women  
Potential clinical 
application 
Probiotic 
API/Pharmaceutical form 
or product 
Type of study, type and number of 
patients and treatment scheme 
Results Reference 
Treatment adjunct to 
antifungal treatment (with 
fluconazole) of 
vulvovaginal candidiasis 
(VVC) 
Lactobacillus rhamnosus GR-1 
and Lactobacillus reuteri RC-
14 (Chr. Hansen, Denmark; 
minimum 10
9
 CFU of each 
strain per capsule), included in 
oral gelatin capsules. 
Randomized, double-blind and placebo-
controlled trial. Fifty-five women diagnosed 
with VVC were treated with a single dose of 
fluconazole (150 mg) supplemented with either 
2 placebo capsules or 2 oral probiotic capsules 
every morning for 4 weeks. 
Significantly lower presence of cultivable yeast 
and lower vaginal discharge associated with 
itching and burning vaginal feeling, 
dyspareunia and dysuria in the probiotic group 
than the placebo group. 
[77] 
Treatment adjunct to 
antimicrobial treatment 
(with tinidazole) of 
bacterial vaginosis (BV) 
L. rhamnosus GR-1 and L. 
reuteri RC-14 (Chr. Hansen, 
Denmark; minimum 10
9
 colony 
forming units (CFU) of each 
strain per capsule), included in 
oral gelatin capsules 
Randomized, double-blind, placebo-controlled 
trial. Sixty-four women diagnosed with BV 
were treated with a single dose of tinidazole (2 
g) supplemented with either 2 placebo capsules 
or 2 oral probiotic capsules every morning for 
4 weeks. 
Significantly higher cure rate of BV and higher 
numbers of women with normal vaginal 
microbiota in the probiotic group than the 
placebo group. 
[78] 
Treatment  adjunct to 
extended antimicrobial 
treatment (with 
clindamycin and 
metronidazole) of BV  
Commercial products: 1) 
Lactobacillus gasseri DSM 
14869 and L. rhamnosus DSM 
14870 (10
8
 CFU/capsule) in 
EcoVag® vaginal capsules 
(Bifodan A/S, Denmark); 2) L. 
rhamnosus GR-1 and L. reuteri 
RC-14 (at least 10
9
 
CFU/capsule) in LaciBios® 
femina oral capsules (ASA Sp. 
z o.o., Głubczyce, Poland). 
New Lactobacillus mixtures: 
Mix 1, L. crispatus (Lc) 4R5, 
L. gasseri (Lg) 20M39, and L. 
jenseneii (Lj) 22B42; mix 2, Lc 
23B33, Lg 6M9, Lj 12B1; mix 
3, Lc 21M49, Lg 6M9 and Lc 
8R6; mix 4, Lg DSM 14869, L. 
rhamnosus DSM 14870 and Lg 
DSM 15527; mix 5: Lg DSM 
Consecutive treatment, open label, follow-up 
study. 63 women with BV received the 
following treatment: clindamycin (seven days 
course of daily 2% vaginal clindamycin cream 
together with oral clindamycin 300 mg BID for 
7 days); then, probiotic capsules for 5 days; 
after the first menstruation, metronidazole 
vaginal gel for 5 days followed by 5 more days 
with probiotic administration; after the second 
menstruation, new course of vaginal 
metronidazole gel. Groups assayed: group 0, 
EcoVag® vaginal capsules; group 1, 2, 3 and 4, 
vaginal capsules containing the mix 1, 2, 3 and 
4, respectively; group 5, oral capsules 
containing the mix 5; group 6, LaciBios® 
femina oral capsules. 
High cure rate after 6, 12 and 24 months. 
There was no significant difference in cure 
rate depending on which Lactobacillus 
strains were given to the women or if the 
women were colonized by lactobacilli. 
[66] 
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14869, L. rhamnosus DSM 
14870, Lg DSM 15527. These 
mixtures were included in 
gelatine capsules (10
9
 freeze-
dried bacteria per capsule) 
Treatment adjunct to   
antimicrobial treatment 
(with metronidazole) to 
reduce the BV recurrence 
rates  
Lactobacillus acidophilus 
KS400 (at least 10
7
 CFU/dose) 
combined with ultra-low-dose 
estriol (0.03 mg), in a single 
vaginal pessary (Medinova AG, 
Switzerland) 
Randomized placebo-controlled double-blind 
trial. 408 women with BV were included in 
analyses and were treated with oral 
metronidazole (400 mg) for 7 days together 
with either 2% vaginal clindamycin-cream for 
7 days or vaginal probiotic or placebo for 12 
days.  
No significant differences in one- and 6-
month BV recurrence between the different 
treatment groups. Therefore, the 
combination of the oral metronidazole 
therapy and vaginal clindamycin, or oral 
metronidazole with a vaginal probiotic, did 
not reduce BV recurrence. 
[79] 
Treatment adjunct to 
antimicrobial treatment 
(with metronidazole) of 
BV 
L. acidophilus (7.5 x 10
8
 CFU) 
and Lactobacillus bifidus (2.5 x 
10
8
 CFU) in oral tablets; and L. 
rhamnosus B, L. acidophilus, 
Streptococcus thermophilus 
and Lactobacillus bulgaricus 
(10 milliard CFU in total) in 
vaginal capsules 
173 women with BV were treated with oral 
metronidazole 500mg twice daily for 7 days 
associated with topical metronidazole cream 
for 5 days. A group of patients did not receive 
any probiotic treatment. Other group of patients  
received the oral probiotic treatment for 10 
days, taking 2 capsules daily at 2 hours after 
the ingestion of the antibiotic. The remaining 
patients used 1 vaginal capsule daily, for 6 
days. The therapy was repeated for 3 
consecutive menstrual periods. 
Lower recurrence rates in patients who 
received probiotic oral capsules while taking 
an antibiotic. Three or more BV relapse 
episodes per year in more than a half of 
women who did not use any probiotic 
product. 
[80] 
Restoration of the vaginal 
microbiota and reduction 
of recurrences in women 
with BV and/or VVC after 
treatment with 
clindamycin and/or 
clotrimazol 
L gasseri LN40, Lactobacillus 
fermentum LN99, 
Lactobacillus casei subsp. 
rhamnosus LN113 and 
Pediococcus acidilactici LN23 
(10
8
-10
9 
CFU of freeze-dried 
bacteria) in vaginal capsules 
(Ellen AB, Sweden) 
Randomized double-blind placebo controlled 
study. After conventional treatment of BV 
(local clindamycin 100 mg ovules) and/or VVC 
(clotrimazol 200 mg vaginal tablets) for 3 days, 
95 women assigned to receive probiotic vaginal 
capsule (n = 60) or placebo (n = 35) twice 
daily, for 5 consecutive days 
High number of patients colonized by LN 
strains 2-3 days after administration, but the 
number decreased after one menstruation 
and after six months after administration. 
High cure rate in women receiving LN 
strains. Lower occurrence of malodorous 
discharge and somewhat fewer recurrences 
in probiotic group compared with placebo. 
[81] 
Restoration of vaginal 
ecosystem balance and 
reduction of the 
recurrence of BV after 
traditional oral treatment 
L. rhamnosus (>40000 
CFU/tablet) in Normogin® 
vaginal tablets (Baldacci, Pisa, 
Italy) 
49 women diagnosed with BV were treated 
with a twice daily dose of 500 mg oral 
metronidazole for 7 days. Then, only a group 
of patients (n = 24) was treated with a once-
weekly probiotic vaginal application for 6 
Balanced vaginal ecosystem in almost all 
patients of probiotic group during 12 
months. Significant increase in the number 
of women with abnormal flora over time, in 
the group that did not receive probiotic 
[82] 
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with metronidazole months. administration after metronidazole therapy.  
Restoration of the vaginal 
lactobacilli population in 
women with BV after 
conventional antibiotic 
treatment with 
metronidazole gel 
L. crispatus CTV-05 (2 × 10
9
 
CFU/dose) LACTIN-V powder 
that is administered using a 
prefilled tampon-like vaginal 
applicator (Osel, Inc., Santa 
Clara, CA, USA) 
Phase 2a trial to determine the colonization 
efficiency, safety, tolerability, and acceptability 
of LACTIN-V administered by a vaginal 
applicator. Twenty-four women with BV 
(previously treated with 0.75% topical 
metronidazole gel for 5 consecutive days) were 
assigned to placebo group or probiotic group 
for administration of placebo or LACTIN-V, 
respectively, for 5 initial consecutive days, 
followed by a weekly application over 2 weeks. 
A high number of women of probiotic group 
were colonized with L. crispatus CTV-05 at 
Day 10 or Day 28. Some minimal adverse 
effects in probiotic and placebo groups, but 
LACTIN-V was well tolerated and accepted. In 
women not colonized with CTV-05, higher 
vaginal concentration of certain BV-associated 
bacteria (Gardnerella vaginalis and Atopobium 
spp.) 
[83,84] 
Restoration of vaginal 
ecosystem balance after 
traditional treatment of 
BV with metronidazole 
L. rhamnosus Lcr35® (at least 
10
8
 CFU/tablet) in 
Gynophilus® vaginal capsules 
(Probionov, Aurillac, France) 
Randomized, open clinical trial. 60 women 
with bacterial vaginosis were treated with two 
daily oral doses of metronidazole 500 mg for 5 
days, and with local application of 
metronidazole ovules 1000 mg at the 1st and 
the 3rd day. After antimicrobial treatment, a 
group (n = 30) was treated with probiotic 
vaginal capsules two daily doses for 7 days. 
Higher clinical and microbiological efficacy 
when probiotic administration was added to 
the standard antimicrobial therapy. 
Restoration of the microbial balance in the 
vaginal ecosystem in most of patients of 
probiotic group, which could prevent BV 
relapses. 
[85] 
Prevention of recurrent 
urinary tract infection 
(UTI) 
L. crispatus CTV-05 (10
8
 
CFU/capsule) in LACTIN-V 
vaginal gelatin capsules (Osel, 
Inc., Santa Clara, CA, USA) 
Double-blind placebo-controlled trial. One 
hundred women with a history of recurrent UTI 
received antimicrobials for acute UTI and then 
were randomized to receive either LACTIN-V 
or placebo daily for 5 days, then once weekly 
for 10 weeks. 
Significant reduction in recurrent UTI 
(associated with vaginal colonization of L. 
crispatus) in probiotic group compared with 
placebo group.  
[86] 
Improvement of vaginal 
ecosystem status 
L. fermentum 57A, L. 
plantarum 57B and L. gasseri 
57C (1 x 10
8
 CFU of freeze-
dried lactobacilli) in prOVag® 
oral capsules (IBSS BIOMED 
S.A., Poland) 
37 initial patients (25 women finalized the 
study) with intermediate vaginal microbiota 
received probiotic oral capsules once a day for 
60 days.  
Between the 20th and 70th days of the 
study, vaginal and rectal colonization of 
lactobacilli administered. Normalization of 
vaginal health parameters (decrease of 
vaginal pH and increase of total numbers of 
lactobacilli). Absence of adverse events. 
[87] 
Prevention of recurrent 
BV 
L. rhamnosus, L acidophilus, 
and S. thermophilus (8 billion 
CFU/capsule) in Probaclac 
Vaginal capsules (Nicar 
Laboratories, Inc, Blainville, 
Double-blind, randomized, placebo-controlled 
study. One hundred twenty healthy women 
with a history of recurrent BV were assigned to 
daily vaginal prophylaxis with 1 probiotic 
capsule (n = 58 women) or 1 placebo capsule 
Lower recurrence rates for BV and 
Gardnerella vaginalis incidence through 11 
months in probiotic group compared to 
placebo group. Absence of adverse effects in 
the two groups assayed. 
[88] 
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Quebec, Canada) (n = 62 women) for 7 days on, 7 days off, and 7 
days on. 
Treatment and prevention 
of BV 
Lactobacillus brevis CD2, 
Lactobacillus salivarius subsp. 
salicinius FV2, Lactobacillus 
plantarum FV9 (10
9
 
CFU/tablet) in Florisia
TM
 
vaginal tablets (CD Pharma 
India, Pvt. Ltd) 
Randomized, double-blind study in sixty-seven 
patients with BV, 50 with intermediate 
microbiota and 42 with normal vaginal 
microbiota. Administration of one lactobacilli 
tablet or pH tablet inserted into the vagina daily 
at bedtime for 8 days. 
High tolerability and absence of adverse 
effects in probiotic group. Higher BV cure 
rate and reduction in IL-1β and IL-6 vaginal 
pro-inflammatory cytokines in probiotic 
group. In healthy subjects, higher BV 
preventive effect of probiotic tablets than 
that of pH tablets. 
[89] 
Short-term treatment of 
BV and aerobic vaginitis 
L. acidophilus KS400 (at least 
10
7
 CFU/tablet) combined with 
ultra-low-dose estriol  (0.03 
mg), in Gynoflor® vaginal 
tablets (Medinova AG, 
Switzerland) 
Multicenter, randomized, single-blind, active-
controlled pilot study. Forty-six women with 
bacterial vaginosis or aerobic vaginitis were 
treated with either one Gynoflor® vaginal 
tablet or suppository containing 500 mg 
metronidazole daily for 12 or 6 days, 
respectively. 
After 3-7 days post-treatment, similar 
improvement of vaginal microbiota status in 
probiotic and metronidazole groups. After 1 
month, lower positive effect with probiotic 
treatment compared to that with 
metronidazole. 
[90] 
Treatment of BV L. acidophilus UBLA-34, L. 
rhamnosus UBLR-58, L. 
reuteri UBLRu-87, L. 
plantarum UBLP-40, L. casei  
UBLC-42, L. fermentum 
UBLF-31, Bifidobacterium 
bifidum UBBB-55 (10
9 
CFU of 
each strain/capsule) in potential 
probiotic oral capsules UB-
01BV (Provinorm, 
manufactured at Unique 
Biotech Limited, Hyderabad, 
India) 
30 women diagnosed with BV (presenting 
symptoms such as white discharge, pH > 4.7, 
increased discharge, odour, colour of discharge 
and pruritus) were assigned to receive two 
potential probiotic oral capsules UB-01BV a 
day for 7 days 
Significant positive response (reduction in 
BV symptoms) in all subjects at the end of 
the treatment. Absence of adverse effects.  
[91] 
Treatment of BV Lactobacillus delbrueckii 
subsp. lactis DM8909 (10
9 
CFU) in vaginal capsules 
One hundred fifteen women, consisting of 30 
healthy subjects, 30 BV-positive control 
subjects, 30 subjects with BV treated with a 7-
day intravaginal metronidazole regimen (500 
mg once daily), and 25 subjects with BV 
treated with a 10-day probiotics regimen (once 
daily), were analyzed.  
At day 30, significant higher BV cure rate in 
the probiotics-treated subjects compared to the 
metronidazole-treated subjects. Reduction in 
the taxa diversity and eradication of most of 
the BV-associated phylotype after 
metronidazole treatment. In probiotic group, 
gradual and steady re-establishment of vaginal 
[92] 
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homeostasis.  
Treatment of BV, VVC 
and trichomoniasis 
L. rhamnosus GR-1 and L. 
reuteri RC-14 (> 10
9
 CFU of 
each strain per capsule), 
included in oral capsules 
(Lactogyn, JGL, Rijeka, 
Croatia). 
Double-blind, randomized, multicentric, 
placebo-controlled study. 544 women 
diagnosed with vaginal infection (bacterial 
vaginosis, candidiasis, trichomoniasis or 
combination of these conditions) received 
either two probiotic (395 subjects) or placebo 
capsules (149 subjects) per day over a period of 
6 weeks. 
Restitution to balanced vaginal microbiota in a 
significantly higher number of subjects in the 
probiotic group, compared to the placebo 
group. 
[93] 
Treatment of VVC L. fermentum LF10 (DSM 
19187) and L. acidophilus 
LA02 (DSM 21717) (at least 
0.4 billion live cells of each 
strain) in slow release 
effervescent vaginal tablets 
(ActiCand 30 product; 
Probiotical, Novara, Italy) 
30 women with VVC (including 8 menopausal 
women) received an acute treatment for 4 
weeks: administration of a vaginal tablet once a 
day for 7 days, followed by 1 tablet every 3 
nights for a further 3-week application. In the 
following month, patients used 1 tablet per 
week. 
After 28 days and 2 months, significant 
resolution of VVC in most subjects. 
[94] 
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Table 2. Effects of probiotic microorganisms on the human urogenital tract: Clinical assays performed in pregnant women  
Potential clinical 
application 
Probiotic 
API/Pharmaceutical 
form or product 
Type of study, type and number of patients 
and treatment scheme 
Results Reference 
Preventing of the 
occurrence of abnormal 
vaginal microbiota and of 
the alteration of 
parameters relevant to 
preterm birth 
L. rhamnosus BMX 54 
(>40000 CFU) in 
Normogin® vaginal tablets 
(Baldacci, Pisa, Italy) 
Sixty pregnant women were assigned randomly to 
the untreated group (n = 30) or probiotic group (n 
= 30) for vaginal application of one probiotic 
tablet, once a week for 12 weeks. 
Effects evidenced in the probiotic group, 
unlike untreated group: Prevention of the 
increase of pathogenic microorganisms in 
vaginal and/or cervical swabs, non 
significant changes in pH values or vaginal 
discharge, and non significant 
modifications of cervical parameters that 
could represent risk factors of vulnerability 
to preterm delivery. 
[95] 
Modulation of the vaginal 
microbiota and cytokine 
secretion, with potential 
implications in preventing 
preterm birth 
Lactobacillus paracasei, 
Lactobacillus plantarum, 
Lactobacillus acidophilus, 
Lactobacillus delbrueckii 
subsp. bulgaricus, 
Bifidobacterium longum, 
Bifidobacterium breve, 
Bifidobacterium infantis 
and Streptococcus 
thermophilus (at least 900 
billion viable of lyophilized 
bacteria) in VSL#3 sachet 
(VSL Pharmaceuticals, 
Inc.,Towson, MD, USA) 
for oral administration. 
Pilot, not randomized, controlled and perspective 
study. 27 healthy women during last trimester of 
pregnancy were assigned to the control group (n = 
12; without any dietary supplementation) or 
probiotic group (n = 15) for oral administration of 
1 sachet once/day of VSL#3 for 4 weeks from the 
33rd to the 37th week of gestation. 
Effects observed in probiotic group, unlike 
control group: Positive changes in the 
composition of the vaginal microbiota 
(prevention of the decrease of 
Bifidobacterium and of the increase of 
Atopobium) and significant decreases in 
some pro-inflammatory vaginal cytokines. 
[96] 
Treatment of BV Lactobacillus plantarum, 
Lactobacillus acidophilus, 
Lactobacillus delbrueckii 
subsp. bulgaricus, 
Bifidobacterium longum, 
Bifidobacterium breve, 
Bifidobacterium infantis and 
Streptococcus thermophilus 
Fourty pregnant women (between 10th and the 
34th week of gestation) with a diagnosis of BV 
were assigned to: A) probiotic group for oral 
administration of VSL#3®, 2 tablets a day for 5 
days, followed by 1 tablet daily for 10 days, or B) 
clindamycin group for vaginal administration of 
clindamycin 100 mg daily for 15 days. 
After treatment, vaginal discharge was 
absent in probiotic group, and reduced in 
clindamycin group. Improvement of 
constipation only in the probiotic group. 
Vaginal swabs resulted negative in both 
groups in particular for Gardnerella 
vaginalis. 
[97] 
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(at least 225 billion viable of 
lyophilized bacteria) in 
VSL#3 capsules (VSL 
Pharmaceuticals, 
Inc.,Towson, MD, USA) for 
oral administration. 
Reduction of Group B 
Streptococcus (GBS) 
vaginal colonization 
L. acidophillus (> 7.5 x 10
9
 
CFU), Bifidobacterium 
lactis (> 6.0 x 10
9
 CFU) and 
B. longum (> 1.5 x 10
9
 
CFU) included as freeze-
dried cultures in Florajen3 
oral capsules (American 
Lifeline Inc., USA). 
Open-label, two-group quasi-experiment pilot 
study. Administration of oral probiotic (Florajen3) 
taken once daily to ten pregnant participants; 10 
participants served as controls. 
Absence of adverse effects or minor side 
effects in probiotic group; one half 
reported improved gastrointestinal 
symptoms. Positive qualitative prenatal 
GBS cultures at 36 weeks of gestation in 
two women in each group. However, 
lower quantitative GBS colony counts in 
the probiotic group. 
[98] 
Prevention of spontaneous 
preterm delivery 
associated with bacterial 
vaginosis (BV) 
Lactobacillus rhamnosus 
GR-1 and Lactobacillus 
reuteri RC-14 (more than 
10
6
 colony forming units 
(CFU) of each strain), 
included in oral capsules 
Randomized controlled trial. Pregnant women at 
less than 20 weeks of gestation, with no indication 
of elective preterm delivery, with asymptomatic 
bacterial vaginosis/intermediate-degree infections. 
317 and 323 patients, respectively assigned to the 
placebo and probiotic groups, finished the trial. 
Oral administration of two capsules per day up to 
the 24th to 26th week of gestation (treatment 
duration: 6-12 weeks). 
No significant differences in the relative 
risk of spontaneous premature birth 
between probiotic-treated and placebo 
groups. 
[99] 
Ampicillin prophylaxis 
accompanied by 
Lactobacillus casei 
rhamnosus to prolong the 
latency period (period 
through which the fetus is 
exposed to a potentially 
unfavorable intrauterine 
environment) in patients 
with preterm premature 
rupture of membranes 
(PPROM) remote 
L. casei rhamnosus (>40000 
CFU) in Vagi-Flora® 
vaginal capsules 
(Laboratoires Lyocentre, 
Aurillac, France)  
Retrospective study. Pregnant patients who were 
admitted for PPROM at 23–31 weeks of 
pregnancy (without infection findings at 
admission) were classified into two groups: group 
1 (n = 20), patients who received four doses of 1 
g/day ampicillin, and group 2 (n = 20), patients 
who received four doses of 1 g/day ampicillin plus 
a transvaginal application of 1 capsule/day, until 
labor of L. casei rhamnosus. 
Gestational weeks at delivery (28.1 ± 0.3 
weeks versus 31.5 ± 0.4 weeks), latency 
periods (12.3 ± 1.5 days versus 41.4 ± 4.4 
days), 5-minute APGAR scores (indicating 
how well the newborn is doing outside the 
mother's uterus), and birth weights were 
significantly higher in group 2. White blood 
cells (WBC) and neutrophil counts at 
delivery, ΔWBC levels, ΔC-reactive 
protein levels and Δneutrophil levels were 
significantly lower in group 2 at delivery. 
[100] 
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Table 3. Effects of probiotic microorganisms on the human urogenital tract: Clinical assays performed in post-menopausal women  
Potential clinical 
application 
Probiotic 
API/Pharmaceutical 
form or product 
Type of study, type and number of patients 
and treatment scheme 
Results Reference 
Non-antibiotic prophylaxis 
for recurrent urinary tract 
infections (UTIs) 
Lactobacillus rhamnosus 
GR-1 and Lactobacillus 
reuteri RC-14 (Chr. Hansen, 
Denmark; minimum 10
9
 
colony forming units (CFU) 
of each strain), included in 
oral capsules 
Double-blind non-inferiority trial, in 252 
postmenopausal women with recurrent UTIs. For 
12 months of prophylaxis, administration of: 1) 
trimethoprim-sulfamethoxazole (480 mg) 1 tablet at 
night and 1 placebo capsule twice daily or 2) 
probiotic oral capsules twice daily and 1 placebo 
tablet at night. 
Probiotics did not meet the non-inferiority 
criteria in the prevention of UTIs when 
compared with trimethoprim-
sulfamethoxazole. At least 1 symptomatic 
UTI occurred in 69.3% and 79.1% of the 
antimicrobial- and lactobacilli-treated 
patients, respectively. However, unlike 
trimethoprim-sulfamethoxazole, lactobacilli 
do not increase antibiotic resistance in 
Escherichia coli from feces and urine. 
[101] 
Positive modification of 
the vaginal microbiome 
and host response 
L. rhamnosus GR-1 and L. 
reuteri RC-14 (Chr. Hansen, 
Denmark; minimum 2.56 x 
10
9
 colony forming units 
(CFU) of each strain), 
included in vaginal capsules 
Double blinded, placebo-controlled crossover study, 
in fourteen post-menopausal women (natural 
menopause) with an intermediate Nugent Score (4-
6). Administration of probiotic vaginal capsules or 
placebo twice a day for 3 days. 
When compared to placebo, the probiotic 
treatment did not result in an improved 
Nugent score. However, subtle molecular 
changes were evidenced: an increase in the 
relative abundance of Lactobacillus 
(associated with an increase in lactate 
levels), a decrease in Atopobium and a 
modulator effect on immune response. 
[102] 
Long-lasting treatment to 
prevent bacterial vaginosis 
(BV) in women with 
history of recurrences, 
undergoing surgical 
menopause 
L. rhamnosus (at least 10
6
 
CFU of live and lyophilized 
bacteria) in Normogin® 
vaginal tablets (Baldacci, 
Pisa, Italy) 
22 patients affected by recurrent BV and treated for 
surgical menopause for benign pathology. 
Administration of one tablet/day for 6 days, then 
two tablets per week for 2 months and then one 
tablet once a week till 6 months. 
One episode of recurrence in 7 out of 21 
women that completed the treatment; two 
episodes of BV during the year successive to 
menopause in 2 patients. Absence of side 
effects. 
[103] 
Local treatment and 
relapse prevention of post-
menopausal vaginal 
atrophy 
Lactobacillus acidophilus 
KS400 (10
8
 CFU) combined 
with ultra-low-dose estriol  
(0.03 mg), in Gynoflor® 
vaginal tablets (Medinova 
AG, Switzerland) 
Double-blind, randomized, placebo-controlled 
study (Controlled phase-initial therapy) followed by 
an open-label follow-up (Open phase-test 
medication initial and maintenance therapy). 87 
postmenopausal women (natural or surgical 
menopause) with vaginal atrophy symptoms and 
Vaginal Maturation Index (VMI) of ≤ 40% 
completed the study. Administration of one vaginal 
Controlled phase: Increase in VMI in 
probiotic-treated women compared to 
placebo. Open phase: Further increase in 
VMI after initial therapy and during 
maintenance therapy. Maturation of 
epithelium, followed by improvement of 
clinical symptoms and normalization of the 
vaginal ecosystem. 
[104] 
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tablet daily for 12 days (initial therapy with test 
medication or placebo in first phase), followed by 
one tablet on two consecutive days weekly for 12 
weeks (maintenance therapy). 
Treatment of atrophic 
vaginitis in breast cancer 
(BC) patients taking non-
steroidal aromatase 
inhibitor (NSAIs) 
Lactobacillus acidophilus 
KS400 (10
8
 CFU) combined 
with ultra-low-dose estriol  
(0.03 mg), in Gynoflor® 
vaginal tablets (Medinova 
AG, Switzerland) 
Phase I pharmacokinetic (PK) study assessed 
circulating estrogens in 16 BC patients during a 
NSAI treatment with vaginal atrophy. Application 
of one daily probiotic vaginal tablet for 28 days 
followed by a maintenance therapy of 3 tablets 
weekly for 8 weeks. 
Small and transient increases in serum 
estriol, but not estrone or estradiol. 
Resolution or improvement of vaginal 
atrophy in all women. The product was 
well tolerated and can be considered as 
safe and efficacious. 
[105] 
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Table 4. Technological studies of probiotic or potential probiotic microorganisms for their inclusion in vaginal pharmaceutical products 
Process Microorganism (API) Type of study Results Reference 
Freeze-drying (for 
potential inclusion 
in a pharmaceutical 
formulation) 
Lactobacillus paracasei CRL 1289, 
Lactobacillus acidophilus CRL 
1266, L. acidophilus CRL 1251, 
Lactobacillus gasseri CRL 1259, 
Lactobacillus johnsonii CRL 1294 
and Lactobacillus salivarius CRL 
1328 
Survival and expression of beneficial 
characteristics during freeze-drying and 
storage at 4°C for 24 months, in the 
presence of lyoprotectors (lactose and 
sucrose suspended in water or 
reconstituted skim milk). 
High degree of survival and expression of 
potentially probiotic characteristics 
(production of antimicrobial substances or 
auto-aggregation capabilities) of most strains 
after freeze-drying and storage, in the 
presence of lactose and sucrose in water or in 
skim milk. 
[231] 
Lactobacillus rhamnosus Lcr35® Viability in laboratory freeze-dried 
powders (obtained in De Man-Rogosa-
Sharpe and reconstituted milk) and stored 
at different temperatures (20, 25 and 30°C) 
for 12 months, according the ICH 
Guideline Q1A. Application of the 
Arrhenius model to predict strain stability 
during storage. 
Higher lost of bacterial viability at higher 
temperature and at higher length of storage. 
The Arrhenius model applied was suitable to 
predict the loss of bacterial viability under 
different storage conditions.  
[233] 
Microencapsulation 
(for potential  
inclusion in a 
pharmaceutical 
formulation) 
Lactobacillus fermentum 
CECT5716 
Development of an emulsification/gelation 
process to encapsulate a freeze-dried 
probiotic strain, using sodium alginate.. 
High amount of viable L. fermentum 
CECT5716 in the microparticles obtained.  
[234] 
Lactobacillus rhamnosus, L. 
salivarius, Lactobacillus brevis and 
Lactobacillus plantarum 
Optimization of the emulsification/gelation 
process to encapsulate probiotic 
suspensions and prebiotics, using 
bioadhesive polymers (pectin and 
hyaluronic acid sodium salt). 
High number of encapsulated viable bacteria 
in the final microparticles. Complete release 
of probiotic strains in a simulated vaginal 
fluid at 37°C. The bioadhesive delivery 
system obtained could be incorporated in 
vaginal gels or tablets.  
[70] 
Pharmaceutical 
formulation and 
shelf life 
Lactobacillus crispatus GAI 98332 Elaboration of vaginal suppositories 
containing freeze-dried bacterium mixed 
and solidified with Witepsol H15. 
Bacterial viability in suppositories stored 
at 4°C, during 8 weeks. 
The number of viable L. crispatus GAI 
98332 did not decrease over time during 
storage at 4°C. 
[235] 
Lactobacillus paracasei HL32 Development of different vaginal 
suppositories containing freeze-dried 
lactobacilli: 1) a conventional suppository 
with Witepsol H-15 as a base, 2) a 
conventional suppository with mixed 
The hollow-type suppository with mixed 
PEGs as the base gave the highest release of 
L. paracasei HL32 and was microbiological 
stable after storage at 2-8°C over the period 
of 3 months. 
[236] 
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polyethylene glycols (PEGs) as a base, 3) 
a hollow-type suppository with Witepsol 
H-15 as a base and 4) a hollow-type 
suppository with mixed PEGs as a base. 
Bacterial viability during storage  at 
ambient temperature (30 ± 2°C) and 2-8°C 
for 3 months. 
Lactobacillus acidophilus 
(unspecified strain) 
Development of different vaginal 
suppositories containing freeze-dried 
lactobacilli: solid body and hollow-type 
suppositories with PEG 400 and 4000 or 
Witepsol H12. Characterization of 
suppositories: organoleptic properties, 
mass uniformity, disintegration, breaking 
strength and L. acidophilus in vitro 
release. 
PEG 400, PEG 4000 and Witepsol H12 
showed the absence of toxicity when tested 
using different vaginal cell lines. Obtained 
vaginal suppositories presented uniform and 
mild texture and a content of about 1 x 10
8
 
colony-forming units, were completely 
disintegrated in simulated vaginal 
environment in less than 60 min and 
provided sustained in vitro release of L. 
acidophilus. There was no significant loss of 
freeze-dried viable bacteria during release 
assays. 
[237] 
Pediococcus pentosaceus SB83 Survival and antilisterial activity after 
freeze-drying and manufacture of vaginal 
formulations (lyophilized powder with 
excipients and tablets with and without 
hydroxypropyl methylcelluloses as 
retarding polymer) and during storage at 
4°C and at room temperature for 12 
months. 
Higher survival of P. pentosaceus SB83 
during storage at 4°C, in the different vaginal 
formulations. Lost of antilisterial activity in 
the tablets; antimicrobial activity was 
maintained in lyophilized bacteria after 
storage at 4°C for 12 months. 
[238] 
Pediococcus pentosaceus SB83 Survival and functional properties of 
bacterial suspension in a liquid system 
(glycerol for eventually formulating a 
vaginal gel) during storage at 4°C and at 
room temperature  
The vaginal probiotic incorporated into 
glycerol was able to survive in simulated 
vaginal fluid. The viability and antilisterial 
activity declined during storage at different 
temperatures; viability loss was total after 13 
weeks at 4°C 
[239] 
Lactobacillus rhamnosus Lcr35® Stability of strain biological properties 
during manufacture of vaginal capsules 
(GYNOPHILUS Lcr Regenerans®). 
Compared with the native strain, bacteria 
from the vaginal formulation GYNOPHILUS 
evidenced: increased ability to metabolize 
[240] 
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glycogen and to produce lactic acid, and 
higher in vitro growth inhibition of the 
pathogen Candida albicans. 
Lactobacillus rhamnosus Lcr35® Bacterial viability, genetic stability and 
maintenance of biological strain properties 
during tableting at different compression 
pressures. Viability in accelerated storage 
conditions. Application of a mathematical 
model to predict strain viability during 
manufacture process. 
Greater bacterial viability in tablets than in 
freeze-dried powders. After compaction, 
genetic stability of Lcr35® strain and 
maintenance of its ability to inhibit the C. 
albicans growth. Development of a new 
mathematical model combining compression 
and temperature parameters to predict the 
bacterial viability at any pressure and time. 
[241] 
Lactobacillus gasseri ATCC 33323 Development of a novel pod-intravaginal 
ring (IVR) technology where polymer-
coated tablets ("pods") of the probiotic 
strain are embedded in silicone IVRs. In 
vitro API release through a delivery 
channel and viability. 
Release of a high number of bacterial cells 
per day (depending on the diameter of the 
delivery channel) for up to 21 days, in a 
sustained and controlled way. Bacteria in the 
IVR pods remained viable throughout the in 
vitro studies and formed biofilms on the 
surfaces of the devices. 
[242] 
L. salivarius CRL 1328, L. gasseri 
CRL 1266 and their combination 
API compatibility during freeze-drying 
and storage in gelatin capsules at 4°C for 
12 months, in different formulations 
including potential probiotic strains, a 
bacteriocin (salivaricin CRL 1328), 
lactose, inulin and ascorbic acid. 
Compatibility of both microorganisms in 
multi-strain formulations together with 
lactose, inulin and ascorbic acid. Only L. 
salivarius CRL 1328 could be included in a 
single-strain formulation together with 
salivaricin and non-microbial substances. 
[73] 
Combination (SYNBIO®) of L. 
rhamnosus IMC 501® and L. 
paracasei IMC 502® 
Preparation of ovules and douches using 
lyophilized microorganisms included in 
different matrixes. 
Witepsol® ovules have proved the best 
formulation in terms of probiotic viability 
[212] 
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